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1 
Outline of the thesis 
Cadherin-catenin complex has been considered as important molecules to modulate 
an initial step of the metastatic cascade of cancers. So far, mechanism and 
relationship of this cell adhesion complex is not identified in renal cell carcinoma 
(RCC).  Chapter 1 reviews molecular prognostic factors in RCC and the necessity 
to determine prognostic tumor markers, with emphasis on metastatic potential, to 
identify the patients who are at risk for metastasis after nephrectomy.  Particular 
attention is paid to the cell adhesion molecule E-cadherin.  
 
In Chapter 2, cadherin expression of RCC is described, as determined by 
immunoprecipitation techniques. In this chapter, it is concluded that cadherin-6 
and N-cadherin are the major cadherins in RCC cell lines and are the most likely 
candidates to participate in a cell adhesion complex. 
 
In Chapter 3, expression of E-cadherin, three catenins, and p120cas in frozen tissue 
of 90 RCC specimens as determined by immunohistochemistry, and their 
significance as prognostic markers was evaluated.  
 
In view of the strong cadherin-6 expression observed in RCC cell lines, it is 
hypothesised that cadherin-6 might be important in cell-cell adhesion in the kidney. 
Chapter 4 provides an immunohistochemical study where the relationship between 
prognosis and cadherin-6 expression of RCC was examined. The result suggested 
that cadherin-6 is the major cadherin in renal tissue, playing an essential role in 
cell-cell adhesion in E-cadherin-negative RCC. 
 
In Chapter 5, the pattern of cadherin expression in fetal, adult, and neoplastic 
kidney is described. It also provides a relationship between alteration of cadherin 
expression and kidney development and carcinogenesis.  
 
Chapter 6 provides a summary and general discussion. 
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Abstract 
 
Renal cell carcinoma (RCC) is characterized by an unpredictable clinical course. 
Therefore, prognostic factors are urgently needed. So far, clinical staging is the most 
powerful predictor of the progression of RCC. A better understanding of cell 
biological and molecular changes associated with the development of this disease is 
urgently needed. Recently, application of a number of these has been tested. 
Whereas some do not seem to have prognostic value over the available classical 
prognostic markers, quantitative nuclear morphometric measurement and 
assessment of cadherin-mediated adhesion complexes (catenin 
immunohistochemistry) have opened new prospectives.  
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I. Introduction 
In the development of cancer, acquisition of metastatic potential is clinically 
most relevant, since curative therapeutic intervention then becomes difficult.  
Clearly, a better understanding of the metastatic cascade is urgently needed, not 
only for prognosis assessment but also as a rational basis for definition of 
therapeutic targets. Classical cadherins are transmembrane proteins.  Their 
extracellular domain interacts with cadherins of neighboring cells, thus mediating 
cell-cell adhesion.  Their cytoplasmic domain is linked to the actin cytoskeleton 
through two types of macromolecular complexes.  In some cases, the link between 
cadherin and actin is made by β-catenin and α-catenin, in the others it is made by 
γ-catenin (also called plakoglobin) and α-catenin [1].  Classical cadherins form a 
family of proteins, each member of which is expressed in a tissue specific fashion.  
E-cadherin is mainly expressed in epithelia. Beside adhesive properties, E-cadherin 
is also implicated in the maintenance of tissue differentiation and integrity [2,3].  
Experimental evidence accumulated to date indicates that E-cadherin can function 
as a molecular switch controlling the invasive phenotype.  Indeed, interfering with 
the functional E-cadherin using blocking antibodies or antisense transcripts results 
in the acquisition of invasiveness of canine kidney cells and mouse mammary cells 
[4,5].  Conversely, transfection of E-cadherin in E-cadherin negative invasive cell 
lines can result in reversion to a non-invasive phenotype [5-7].  These results have 
recently been confirmed in vivo, using an elegant transgenic mice model of 
pancreatic carcinogenesis [8].  These data were in fact the rational basis of our 
immunohistochemical studies assessing the involvement of E-cadherin in the 
development of prostate and bladder tumors.  Both bladder and prostate tumors 
have an unpredictable clinical course.  Upon initial diagnoses most bladder tumor 
(50-80%) are superficial and can be surgically removed by transurethral resection.  
However, recurrences are frequently observed (57-85%) and at that time, 4 to 30% of 
the tumors are invasive. At present, the identification of the tumors that will give 
rise to aggressive recurrence is very uncertain.  Likewise, the clinical course of 
patient with prostate cancer may vary widely, even in patient whose tumors are of 
similar clinical stage and histological grade.  Furthermore, improvements in the 
diagnosis of prostate cancer have resulted in screening programs that reveal many 
more organ-confined lesions that are treated radically.  Thus, E-cadherin 
immunoreactivity in cancer tissue has been shown as prognostic marker in bladder 
and prostate cancer. 
In renal cell carcinoma, significance of E-cadherin expression has not been 
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established because proximal kidney tubule and in its derived tumors E-cadherin 
expression is frequently absent.  Renal cell carcinoma (RCC) is characterized by an 
unpredictable clinical course and tendency to recur and metastasize even several 
years after surgery.  Approximately 30 % of the patients already have metastatic 
disease at the time of diagnosis [9].  A number of investigations showed that the 
extent of tumor spread at the time of diagnosis correlated with survival.  
Depending on the stage of the tumor, the 5-years survival rate ranges from 30 to 
60 % [10].  Unfortunately, there is no curative treatment for patients with 
advanced disease yet.  Nephrectomy remains the only possibility for cure in 
patients with localized disease.  Therefore, patients with disseminated renal 
cancer need adjuvant therapy to improve survival.  New treatment modalities like 
immuno- and chemotherapy are still under investigation.  So far, these therapeutic 
options offer little improvement and result in side effects to the patients.  Thus, it 
is necessary to determine prognostic tumor markers to identify and select the 
patients who are most likely to respond to adjuvant therapy after nephrectomy.  
Therefore, we first introduce the prognostic value of E-cadherin in urological 
malignancies except for RCC, i.e. bladder and prostate cancer, and then show 
classical and previously reported prognostic marker in RCC.  
 
II. E-cadherin expression in bladder and prostate tumors. 
E-cadherin expression was analyzed immunohistochenically with a monoclonal 
antibody.  The bladder samples were composed of 24 superficial and 25 invasive 
tumors [11].  Among the invasive tumors two were squamous cell carcinomas, all 
the others were transitional cell carcinomas.  The prostate samples included 89 
adenocarcinoma surgery specimens [12].  In normal tissues, the presence of a 
functional E-cadherin is visualized by membranous staining outlining regions of 
cell-cell contact, which should be seen in virtually all the cells [13,14].  The same 
pattern is observed in positive tumors.  Considering the role of E-cadherin as an 
invasion suppressor, it is obvious that the decreased expression of E-cadherin even 
in a limited fraction of cells is sufficient to allow the onset of an invasion process.  
We therefore used the following criteria to evaluate the staining: if over 10% of the 
cells were negative or weakly stained, the staining was considered abnormal i.e. it 
was either negative or more often heterogeneous.  In few cases, a cytoplasmic 
staining was observed; these tumors were also classified as abnormal. 
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III. Correlation with pathological data 
We found a strong correlation between decreased E-cadherin expression and 
increasing grade of the tumor for bladder (p<0.01, Table 1) as well as for prostate 
(p<0.001, table 2).  The grading of bladder tumors is based on cytological 
considerations, and the Gleason score used for prostate is based on tissue 
architectural characteristics.  However, E-cadherin expression correlates with both 
these aspects of differentiation.  Accordingly, a correlation with stage was also 
observed (p<0.005) for both tumor types (table 1 & 2).  Correlation with the 
presence of metastasis at diagnosis was possible for prostate only and was found 
highly significant (p<0.001).  This supports the classification of E-cadherin as an 
invasion suppressor molecule.  However, when we analyzed prostate metastases, 2 
out of 8 had a normal staining pattern [15].  Similar observations have been made 
by others [16,17].  This is not really in contradiction with the proposed role of 
E-cadherin as an invasion suppressor gene since it is possible that E-cadherin has 
been transiently down regulated like already reported in model systems [18-20].  
Alternatively, other mechanisms may have overcome the invasive suppressor 
function of E-cadherin. 
Correlation with pathological data has been found in many types of cancer and 
seems to have a general significance.  Since grade and stage are classical prognosis 
factors, we went on to investigate the prognostic value of E-cadherin staining. 
 
IV. Prognostic value of E-cadherin and its related protein immunostaining 
In patients with bladder tumors, analysis of the survival during 3 years after 
tumor resection revealed that abnormal immunoreactivity strongly correlated with 
poor prognosis (χ2=16.5, p<0.001 by log rank test, fig 2).  This correlation seems to 
persist when only invasive tumors are analyzed (χ2=3.7, p<0.006 by log rank test).  
For superficial tumors, too few events (3 deceases and 1 progressive disease) have 
been observed to enable any analysis of this subgroup.  
For prostate cancer, the 3-year survival of patients with normal E-cadherin 
expression was significantly better than that of patients with abnormal staining 
(χ2=20.4, p<0.001 by log rank test fig 3).  Since this group is heterogeneous, we 
stratified according to treatment: radical prostatectomy, which is performed when 
the disease is confined to the prostate and palliative transurethral resection of the 
prostate.  Strikingly, progression after radical prostatectomy occurred in 67% (10 
to 15 %) of patients with abnormal E-cadherin expression versus 4% (1 to 27) of 
patients with normal staining.  Analysis of the disease free interval revealed that 
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patients with abnormal staining were at higher risk for progression (χ2=9.4, 
p<0.005 by log rank test, fig 3).  Moreover, in the group of patients with locally or 
distantly progressive cancer, that were treated by palliative transurethral resection 
of the prostate, the analysis of survival revealed that abnormal E-cadherin staining 
is significantly correlated with poor prognosis (χ2=15.1, p<0.001). 
We have also analyzed α-catenin expression in prostate tumors and expression 
of all three catenins in bladder tumors. Expression of α-catenin is highly correlated 
to E-cadherin expression in both tumor types.  Likewise, β-catenin expression is 
tightly correlated to E-cadherin expression in bladder tumors and both α- and 
β-catenin have prognostic value similar to that of E-cadherin.  The correlation 
between E-cadherin and γ-catenin expression is a little bit less tight.  Our studies 
revealed the potential of E-cadherin immunohistochemistry as a prognostic tool, in 
prostate and bladder cancer.  They have been generally confirmed since then, using 
archival tumor samples [21,22].  The prognostic value of E-cadherin staining is 
also documented in gastric, colon, breast, and thyroid cancer [23-26].  
Unfortunately, it has not been identified which cadherin is expressed in RCC and 
normal kidney yet. 
 
V. Clinical prognostic factors for RCC 
The prognostic significance of sex or age of patients [27-30] remains 
controversial; no definitive relationship between survival and these parameters can 
be proven.  Performance status of patients with metastatic disease, however, is a 
powerful independent prognostic factor [31, 32].  Weight-loss was also described as 
a bad prognostic sign [28-30].  From “classical” laboratory parameters, an elevated 
erythrocyte sedimentation rate (ESR) was found to be a bad prognostic sign [33, 34], 
although this was not confirmed in a young adult population [28]. 
There is a positive prognostic significance for tumor stage, or absence of 
metastasis [35-38] according to the pathological TNM classification after 
nephrectomy [39].  Although the venous involvement seems to be a bad prognostic 
sign, the survival rate of patients with vena cava involvement is not worse if it can 
be removed radically [40, 41]. 
The histopathological grading according to the WHO criteria [42] describes 
nuclear atypia, including the size of nucleoli, supplemented by some cytoplasmic 
features.  However, this grading system suffers from interobserver variability, 
despite the modification to simplify the grading criteria [43, 44].  Thus, the use of 
various grading systems will not be beneficial for comparative analyses.  Another 
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problem in grading is the heterogeneity of the tumor.  For this reason, the 
importance of grade for prognosis is diminishing.  Reis [45] looked for a more 
reproducible way of grading by using the histological pattern as a prognostic factor.  
The implications on prognosis of these patterns are still controversial, especially for 
papillary tumors [49-49].  However, there are some characteristics, which are 
related to survival: i.e. patients with spindle cell carcinoma have a poor prognosis 
[50].   
 
VI. Proliferation markers 
The proliferative potential of tumors can be measured by PCNA or Ki-67 (S 
phase fraction or growth fraction, respectively).  It has been reported that PCNA 
expression was not associated with clinical behavior [51].  Another investigation 
showed that PCNA expression correlated with presence of advanced disease at the 
time of surgery [52].  However, independent prognostic significance of expression of 
this antigen was not confirmed.  Proliferation rate assessed by Ki-67 expression 
did not correlate with pathological tumor stage, whereas a strongly significant 
correlation was observed between proliferation rate and tumor grade, as well as 
recurrence rate.  In multivariate regression analyses, proliferation rate was 
independent prognostic marker for RCC [53, 54].  Recently, labeling index based on 
MIB1 antibody, which was available in formalin fixed paraffin embedded sections, 
was thought to be a predictor for survivals in RCC [55, 56].  In another study, silver 
staining nucleolar organizer region (NOR) index was shown as independent 
prognostic marker for patients with RCC [57, 58].  However, a large difference in 
scoring between the studies was observed, suggesting that the reproducibility 
remained controversial.  Moreover, correlations between proliferation activity, 
tumor aggressiveness and NOR are not yet clear.  
 
VII. New development in karyometric analyses in RCC 
Recently, nuclear morphometric analyses have been used successfully to predict 
the outcome of patients with cancer when classical pathologic grading systems 
failed.  Indeed several investigations showed a significant correlation between 
morphometric parameters and survival of patients with RCC [47, 59-61].  van der 
Poel et al. [62] have developed an objective nuclear “grading” system for RCC using 
automated image analysis.  Thus, karyometric features including nuclear profile 
area, nuclear profile perimeter, elongation factor, nuclear roundness factor, 
maximal nuclear diameter and optical density were measured.    Cox's regression 
Chapter 1 
 
 
 
10 
analyses revealed that karyometric features could provide independent predictive 
values for tumor stage and, moreover, clinical characteristics.  Especially, 
karyometric parameters associated with tumor heterogeneity (e. g. differences in 
nuclear size and chromatin texture between tumor subpopulations) were of value in 
predicting prognosis.  In addition, heterogeneity of chromatin patterns within the 
tumors quantified in karyometric analyses appeared to be the karyometric feature 
strongest correlated with tumor progression in patients with a localized 
(T1-3N0M0) RCC [63].  In contrast, comparative study with DNA flowcytometry 
has revealed that flowcytometry did not correlate with survival.  Another study 
using flowcytometry showed that DNA contents correlated with presence of 
metastasis but not with survival [64]. 
Recently it has become widely accepted that genetic alterations play an 
important role in the development of many cancers.  The relationship of abnormal 
nuclear morphology to molecular genetic alterations in RCC is unknown.  In 
colorectal carcinoma, it was shown that nuclear morphology seemed not to be 
directly influenced by the individual genetic alterations but was by fractional allelic 
loss (i.e. a global measure of genetic changes) [65].  Thus, it might be suggested 
that complex tumor properties such as pathologic appearance and metastatic 
potential cannot be understood unless most of the underlying genetic factors are 
taken into consideration. 
 
VIII. Molecular prognostic marker 
1. Oncogenes and tumor suppressor genes 
A number of investigations have shown that the VHL gene predisposes to 
develop RCC.  The VHL gene is linked to the locus encoding the human homologue 
of the RAF1 oncogene, which maps to chromosome 3p25 [66].  The VHL gene 
functions as a tumors suppressor gene and is implicated in both sporadic and 
familial forms of RCC.  It was shown that LOH of the VHL gene was most 
frequently observed in clear cell carcinoma (98 %), whereas mutations were found in 
57 % of the RCC [67].  In contrast, Kovacs et al. [68] suggested that allelic loss of 
chromosome 3p is infrequent in the papillary subgroup of RCC.  Unfortunately, no 
difference is found in aberration of this gene between localized and advanced RCC 
[69]. 
p53 mutations are found in a number of solid tumors.  p53 tumor suppressor 
gene alterations were also found in RCC [70, 71].  However, prognostic significance 
of mutation in this gene is not clear.  Frequency of mutation of this gene is low (10 - 
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14%) in RCC [70, 72, 73].  Recently it has been reported that mutation of the p53 
gene and p53 protein overexpression are associated with sarcomatoid 
transformation in RCC [70], but not with survival [74].  Other genes often mutated 
in solid tumors, i.e. ras oncogenes, do not seem to play a major role in the initiation 
and maintenance of metastases [70, 75]. 
On the other hand, Lipponen, et al. [50] has studied the expression of the 
retinoblastoma (Rb), c-myc and Bcl-2 proteins by immunohistochemistry in RCC.  
The combination of these genes can play an important role in regulating the growth 
rate of tumors.  It has been shown, however, that the expression of Rb, Bcl-2 and 
c-Myc had no independent prognostic value over T category, mitotic index and 
nuclear grade. 
Genetic alteration involving loss of heterozygosity (LOH) of chromosome 6q, 8p, 
9 and 14q correlated with non-papillary RCC, whereas trisomy of chromosome 3q, 8, 
12, 16 and 20 were associated with papillary RCC [77].  Therefore, LOH of 
chromosome 6q, 8p, 9 and 14q may correlate with clinical behavior of RCC [77].  
However, the prognostic significance of these genes is incompletely understood.  
Foster, et al. [47] have studied allelic loss of known putative tumor-suppressor gene 
loci on chromosomes 5q, 11p, 17 and 22 as well as on chromosome 3p in RCC. 
Consequently, LOH of chromosome 5q, 11p, 17 and 22 was detected in very low rate 
of the tumors as compared with chromosome 3p.  Thus, molecular genetic studies 
of these loci have yet no established prognostic value. 
 
2. Cell adhesion molecules and proteases 
Cancer metastasis is a complex multistage process.  Decreased intercellular 
adhesion enables detachment of tumor cells and can play a role in the early steps of 
the metastatic process.  Although cell-cell adhesion can be mediated through at 
least four families of adhesion molecules (integrin, immunoglobulin, selectin and 
cadherin), E-cadherin, a Ca++ dependent epithelial cadherin, is considered as a 
critical molecule for epithelial integrity [78].  However, most RCCs do not express 
E-cadherin because renal proximal tubular epithelium from which RCCs originate 
does not express E-cadherin [79] (Shimazui, et al., data not shown).  In contrast, 
these epithelial cells of renal proximal tubules express α-catenin, a member of 
cadherin mediated adhesion complex, suggesting other cadherins than E-cadherin 
might be expressed in these epithelial cells and RCCs.  Recent studies showed that 
in normal kidney tubular epithelium N-cadherin is expressed [79] and cadherin 6 
[80].  Thus, better understanding of cadherin expression in RCC is needed to 
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investigate the correlation between expression of this molecule and prognosis.  
In tumor invasion and metastasis, proteases secreted by cancer cells are 
thought to play a role due to their destructive effects on extracellular matrix. 
Cathepsin L is more potent than many other proteases in degrading collagen, 
elastin, laminin, and other component of the basement membrane.  Chauhan, et al. 
[81] has described that mRNA of cathepsin L is expressed at the high level in RCC. 
Although more detailed studies should be undertaken, cathepsin L might become a 
candidate as a prognostic marker. 
 
3. Specific antigens 
Renal specific antigen, for instance antibodies against proximal tubular brush 
border and distal tubular Tamm-Horsfall glycoprotein, RC3, RC69, RC154 and 
RC38, are useful for diagnosis or to differentiate in the cellular origin and 
differentiation of RCC [82-85], whereas prognostic significance of these antigens 
has not been proven. 
 
 
IX. Conclusion 
There is no doubt that abnormal E-cadherin expression is a good marker of 
tumor progression in carcinoma.  Moreover, studies from our laboratory outline the 
potential of E-cadherin immunohistochemistry as a prognostic tool in prostate and 
bladder cancer.  Therefore we propose that the clinical usefulness of this test be 
assessed in a large-scale prospective study. 
It is of particular interest that a major mechanism of defective E-cadherin 
function lies in alteration of E-cadherin transcriptional regulation. Indeed, 
clarifying the mechanisms of this regulation could shed light on fundamental 
aspects of epithelial differentiation and maintenance of epithelial integrity.  This is 
a major concern in cancer research since loss of epithelial integrity is a common 
feature of carcinoma development. Interfering with biochemical pathways 
governing these aspects of tissue homeostasis might provide new therapeutic 
approaches. 
In spite of numerous investigations, tumor stage is still superior to other 
biological and molecular prognostic factors for RCC.  Unfortunately, none of the 
molecular alterations provide additional prognostic information over tumor stage.  
In the immediate future, however, nuclear morphometry, densitometry, α-catenin 
expression and proliferation rate assessed by Ki-67 can be used as prognostic 
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markers for the patients with RCC.  The expression of some kind of cadherins and 
cathepsin L may indicate invasive and metastatic capacity and may thus prove 
useful as a prognosis marker of RCC. 
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Abstract 
 
E-cadherin is an intercellular adhesion protein expressed by most epithelia. 
Decreased expression of E-cadherin correlates with tumor aggressiveness in most 
carcinomas. In renal cell carcinoma (RCC), however, this correlation is not well 
established and the prevalence of negative tumors is higher than in other 
carcinomas. Our immunofluorescence study of alpha-catenin expression in 20 RCC 
cell lines revealed a typical honeycomb staining pattern in all of the lines, whereas 
only six expressed E-cadherin. This suggested that other cadherins are expressed in 
RCC lines. Indeed, immunoprecipitation with an anti-alpha-catenin antibody 
resulted in coprecipitation of proteins of Mr 125,000-135,000. Using Western blot, 
these proteins react with a pan-cadherin antibody. To identify these cadherin 
related proteins, RT-PCR using degenerated primers and sequence comparisons 
was carried out. We then assessed the expression of the identified cadherins. 
N-cadherin mRNA was present in all cell lines; and cadherin 6 mRNA was seen in 
16 lines. Cadherin 11 (mRNA) and E-cadherin (protein) were expressed in five and 
six lines, respectively. A cadherin 4 transcript was observed in only one line, 
whereas no P-cadherin protein could be detected. Expression of the four main 
cadherins was also found in normal kidney (two samples tested) and RCC 
specimens (four samples). Thus, RCC and normal kidney express a complex set of 
cadherins. 
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Introduction 
Cadherins constitute a large family of transmembrane Glycoproteins.  The 
so-called classical cadherins share a common structure, including a highly 
conserved cytoplasmic region, a transmembrane region, and an extracellular 
domain in which homologies define type I and type II cadherins.  The most 
extensively characterized members of this family, E-, P-, and N-cadherins, belong to 
the type I subgroup and mediate Ca2+-dependent cell-cell adhesion in a variety of 
cell types.  Their carboxyl terminus is bound to either β- or γ-catenin (plakoglobin), 
which in turn interacts with α-catenin that bridges the complex to the actin-based 
cytoskelton.  The importance of the correct assembly of this complex is exemplified 
in the fact that cadherins deleted of the 70-carboxyl terminal amino acids are 
unable to mediate cell adhesion. 
In most carcinomas, E-cadherin expression decreases with tumor grade and 
stage [1].  In renal cell carcinoma (RCC), however, E-cadherin expression is found 
infrequently and even low-grade tumors do not express E-cadherin [2].  A possible 
explanation is that the renal proximal tubule epithelium, from which RCCs 
presumably originate, does not express E-cadherin.  Indeed, in normal kidney, 
E-cadherin is expressed in Bowman's capsule and in all tubular segments except 
the proximal convoluted and straight tubules [3]. However, using 
immunohistochemistry we have been able to show α-catenin expression at the 
intercellular borders in all tubules.  Thus, it is likely that functional 
cadherin-catenin complexes are present in all segments of the nephron.  We 
hypothesized that other classical cadherins form complexes with α-catenin and 
mediate cell-cell adhesion in RCC.  In this article, we used RCC cell lines to 
characterize RCC for expression of classical cadherins. 
 
 
Materials and Methods 
RCC cell lines. 
RCC cell lines (a kind gift from Dr. L. J. Old, New York, NY) were cultured in RPMI 
1640 with 10% FCS and 1% glutamine. 
 
Immunohistochemistry. 
Cells were grown on glass slides, fixed with 3% paraformaldehyde, and then 
permeabilized using 0.2% Triton X-100 in PBS.  Monoclonal antibody HECD1 
(Takara) was diluted 1:20 and A-CAM (clone GC4; Sigma) 1:30.  Serum of a mouse 
immunized with a glutathione S-transferase/α-catenin fusion protein (nucleotides 
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454-1981 of human alpha-catenin, kindly provided by Dr. W. Isaacs, Baltimore, MD) 
was diluted 1:1000.  On Western blot, this serum recognized a single band 
comigrating with α-catenin. 
 
Immunoprecipitation.   
Cells were metabolically labeled with [35S] methionine (250 μCi/ml) overnight.  
Proteins were extracted in 2% Triton X-100, 20mM Tris (pH7.4), 150mM NaCl, 
2mM CaCl2, 50ug/ml leupeptin, and 1 mM phenylmethylsulfonyp fluoride.  Protein 
extracts corresponding to 107 cpm were incubated with 1 μl α-catenin mouse 
antiserum.  Complexes were collected with protein G-agarose (Oncogene Science) 
and resolved on a 7% SDS-polyacrylamide gel.  Proteins were transferred onto a 
nitrocellulose membrane.  After overnight autoradiography, the membrane was 
processed for immunoblotting with a pan-cadherin polyclonal antibody diluted 
1:1600 (Sigma). 
 
Western blot. 
Twenty-five μg of proteins were separated using a 7% SDS-PAGE and transferred 
onto nitrocellulose filters.  Immunoblots were analyzed using ECL (Amersham) 
and HECD1 or P-cadherin (Transduction Laboratories), both diluted 1:500. 
RT-PCR.  Total RNA was extracted from the cell lines with TRIzol (Life 
Technologies, Inc) and treated with DNase, and the cDNA was synthesized using 
superscript reverse transcriptase (Life Technologies, Inc).  PCR products were 
subcloned into a pGEM vector and sequenced using sequenase 2.0 (United States 
Biochemical).  A computer-assisted homology search was performed with the 
EMBL (release 44) and Genbank (release 90) nucleotide sequence data bases. 
Northern blotting.  Ten μg RNA were denatured with glycol, separated on 1% 
agarose, and transferred to Hybond N+ membranes.  Probes corresponding to 
nucleotides 579-1643 for N-cadherin, 522-2186 for cadherin-4, 25-465 for cadherin-6, 
and 2759-3256 for cadherin-11 were generated by RT-PCR and labeled with 
[32P]dATP by random priming.  Blots were hybridized overnight in 250 mM 
Na2HPO4 (pH 7.2), 1 mM EDTA, 1% BSA, and 7% SDS at 65oC and then washed at 
65oC successively in 250 mM Na2HPO4 (pH 7.2), 1 mM EDTA, and 1% SDS; in 125 
mM Na2HPO4 (pH 7.2), 1 mM EDTA, and 1% SDS; and in 50 mM Na2HPO4 (pH 7.2), 
1 mM EDTA, and 1% SDS;  To ensure that the expression we evaluated were not in 
vitro artifacts, we also included two normal kidneys and four RCC samples. 
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Results and Discussion 
 Using immunohistochemistry, we found that all of the cell lines expressed 
α-catenin at the cell-cell borders.  In contrast, E-cadherin was expressed in only six 
cell lines (Table 1 and Fig. 1).  Since in L cells, which do not express any cadherin, 
α-catenin is unstable, the staining pattern observed here probably reflects the 
involvement of α-catenin in a protein complex, possibly with a cadherin [5]. 
 
 
 
Table 1  Characteristics of the RCC cell lines and cadherin expressions 
        Cadherin expressiona 
Cell line Morphology  α-catenin E P N 4 6 11 
SKRC-1 Fibroblastic  +  - - +/+  -  +  - 
SKRC-6 Epithelial  +  +  -  wb/+ -  -  - 
SKRC-7 Epithelial  +   -  - +/+ - + - 
SKRC-10 Fibroblastic  +   - - w/+ - w + 
SKRC-17 Epithelial  +       +  - +/+ - + - 
SKRC-18 Epithelial  +  + - +/- - + - 
SKRC-24 Fibroblastic  +       - - +/+ - + - 
SKRC-28 Fibroblastic  +       - - +/- - + + 
SKRC-29 Epithelial  +  + - +/+ - - - 
SKRC-30 Intermediate +  - - +/+ - w - 
SKRC-33  Epithelial  +  - - w/+ + + - 
SKRC-39  Intermediate +  + - +/+ - w - 
SKRC-42  Epithelial  +  - - +/+ - + - 
SKRC-12  Epithelial  +  - - +/+ - + w 
SKRC-14  Epithelial  +  - - +/+ - + - 
SKRC-26  Epithelial  +  - - +/+ - + - 
SKRC-35  Fibroblastic  +  - - +/+ - + + 
SKRC-52  Fibroblastic  +  - - +/+ - - + 
SKRC-59  Epithelial     +  + - +/+ - + - 
SKRC-38  Intermediate +  - - +/+ - - - 
aExpressions were assessed as follows: α-catenin, immunohistochemistry; E-cadherin, 
immunohistochemistry and western blot; N-cadherin, Northern blot (first symbol) and 
immunohistochemistry (second symbols); cadherins 4, 6, and 11, Northern blot. 
bw, weak expression. 
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To investigate which protein stabilized α-catenin, we immunoprecipitated 
α-catenin from seven cell lines; one of them (SKRC-59) expressed E-cadherin.  
Autoradiography after SDS-PAGE revealed several coprecipitating proteins.  One 
of them was present in all of the cell lines and comigrating with α-catenin.  A weak 
band with the same electrophoreic mobility as γ-catenin was found in some cell lines.  
Interestingly, a band coinciding with E-cadherin (Mr 120,000) was present only in 
SKRC-59, but bands corresponding to Mr 125,000-135,000 were observed in all of 
the lines (Fig. 2A).  Western blot analysis of these immunoprecipitates with an 
anti-pan-cadherin antibody showed that the proteins constituting these bands were 
immunologically related to cadherins (Fig. 2B). 
 
 
 
  
Fig. 1: Immunofluorescence staining for E-cadherin (A and B) and α-catenin (C and D) in renal cell 
carcinoma cell lines.  SKRC-12 cells do not express E-cadherin (A) but α-catenin (C) at their cell-cell 
contact sites, whereas SKRC-6 cells express both E-cadherin (B) and α-catenin (D) at the cell-cell 
contact sites.  E-cadherin expression in SKRC-6 is generally weak as compared with α-catenin 
expression.  Note that both cell lines are showing an epithelial phenotype. 
Complex Cadherin Expression in Renal Cell Carcinoma
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Fig. 2: Immunoprecipitation of [35S]-methionin metabolically labeled cell extract using α-catenin 
antibody (A) and its immunoblot with a pan-cadherin antibody (B).  Autoradiography after 
SDS-PAGE shows several copreciptated proteins. A band comigrating with β-catenin is seen all of the 
cell lines, whereas a weak band with the same electrophoretic mobility as γ-catenin is found in only 
SKRC-26, -52, and -59.  A band that coincide with E-cadherin is present only in SKRC-59, however, 
bands corresponding to Mr 125,000 -135,000 are observed in all of the cell lines (A).  Immunoblot 
analysis of these immunoprecipitations with an anti-pan-cadherin antibody is showing that the 
proteins constituting these bands are immunologically related to cadherins (B).  E: E-cadherin, α, β 
and γ: α-, β- and γ-catenin, respectively. 
 
 
 To characterize further these putative cadherins, we performed RT-PCR 
using degenerated primers corresponding to the cytoplasmic region of classical 
cadherins.  Indeed, the pan-cadherin antibody used in the Western blot analysis 
was raised against this part of the molecule.  Because slight differences in the 
eletrophoretic mobility of the cadherin-related bands were noticed, possibly 
reflecting the presence of different proteins, we chose four cell lines representative 
of the various mobilities but not expressing E-cadherin at the protein level (SKRC-7, 
-10, -24, and -52).  Sequence analysis of the RT-PCR products revealed that several 
cadherins are expressed.  N-cadherin was the most frequently cloned and was 
present in the four cell lines (five of five clines in SKRC-24, six of eight in SKRC-52, 
four of eight in SKRC-7, and only one of eight in SKRC-10).  Cadherin-6 was found 
in two cell lines (five of eight clones in SKRC-10 and three of eight in SKRC-7).  
Other cadherins were found in only one line: cadherin-11 (two of eight clones in 
SKRC-10), cadherin-4 (one of eight clones in SKRC-7), P-cadherin (one of eight 
clones in SKRC-52), and E-cadherin (one of eight in SKRC-52). 
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 We then evaluated the expression of these cadherins in our panel of cell lines 
at the mRNA (N-cadherin and cadherin-6, 11, and 4) or protein level (E- and 
P-cadherin). 
 A 3.4-kb N-cadherin transcript was present in all of the cell lines.  Besides 
this major transcript, two minor transcript (3.9 and 2.7 kb) can be seen in some 
lines.  N-cadherin transcripts were found in the two normal kidneys and three of 
four RCCs showing that N-cadherin expression in cell lines is not an in vitro artifact 
(i. e., expression triggered by the culture conditions and not seen in vivo). 
 Transcripts of different sizes have been described for both mouse [6] and 
human N-cadherin [7].  However, the transcripts found in human brain muscle are 
bigger (5.2, 4.3, and 4 kb) than those observed in the RCC cell line.  Interestingly, 
in rat, it has been found that brain, muscle, and heart express a 5.2- and a 4.3-kb 
transcript, whereas lung, kidney, and liver express 4.3- and a 3.5-kb transcript [8].  
It thus appears that the N-cadherin transcripts vary in a tissue specific manner, 
with, in humans, a main 3.4-kb transcript in kidney and RCC.  The significance of 
these size differences is still unknown; evidence for alternative polyadenylation has 
been found in human muscle [7]. 
 The widespread expression of N-cadherin in RCC cell lines was confirmed 
using immunofluorescence (Table 1).  The fact that two lines (SKRC-18 and -28) 
with a clear mRNA expression are negative, as determined with 
immunohistochemistry, probably reveals posttranscriptional regulation.  
Posttranscriptional down-regulation of N-cadherin has indeed been described 
during retinal development [9]. 
 Sixteen of the 20 cell lines as well as the 2 normal kidneys and 3 of 4 RCC 
samples expressed cadherin-6 (Fig. 3).  Four major transcripts (9, 4, 3.4, and 2.7 
kb) were observed in concordance with earlier studies [10].  The 2.7- and 9-kb 
forms were not found in all cell lines.  Moreover, we could clearly wee in some cell 
lines a 4.3-kb transcript which was not described previously by Shimoyama et al. 
[10].  Indeed, this transcript is nor visible in the non-renal cell lines or in the 
normal organs they have tested, but it can be clearly seen in the KT12 RCC 
carcinoma they analyzed.  Thus, this transcript may be kidney specific. 
 Using Northern blot, the previously described 3.5-kb cadherin-11 transcript 
[4] was found in five cell lines (Fig. 3 and Table 1).  Both normal kidneys and one of 
the RCC samples also expressed cadherin-11. 
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Fig. 3: Expression of cadherins in renal cell carcinoma cell lines examined by northern blot (N: 
N-cadherin, 6: cadherin-6, 11: cadherin 11, bA: b-actin) and immunoblot analysis (E: E-cadherin).  A 
3.4 kbp N-cadherin transcript is seen in all the cell lines including only 3 lines with a weak signal 
(SKRC-6, 10 and 33).  Two minor transcripts (3.9 and 2.7 kbp) can be seen in some lines.  Cadherin-6 
transcripts are detected in 16 out of 20 cell lines.  SKRC-10 and -30 have low mRNA expression level. 
Four major transcripts (9, 4, 3.4 and 2.7 kbp) are observed.  Beside these bands, clear 4.3 kbp mRNA 
can be seen in some cell lines.  Cadherin 11 transcript is seen corresponding to the size of 3.5 kbp in 6 
cell lines (SKRC-10, 18, 28, 12, 35 and 52). The expression is weak in 2 lines (SKRC-18 and 12).  Note 
that faint bands related to previous cadherin 6 hybridization can be seen in 2 cell lines (SKRC-18 and 
-33).  E-cadherin is expressed in 6 lines by immunoblot. 
 
 
 
 As previously stated, E-cadherin was expressed at the protein level in six cell 
lines (Table 1).  This frequency is in agreement with other studies on RCC samples 
(19 and 35%).  The frequency of negative cell lines (70%) is very high when 
compared to other cell lines of epithelial origin (e.g., 30% in colon [11], 33% in 
bladder [12], and 55% in breast [13] cancer cell lines), and is probably related to the 
fact that proximal epithelial cells, from which RCC originates, do not express 
E-cadherin. 
 A weak band, corresponding to a 6-kb cadherin-4 transcript, was seen in only 
one cell line (Table 1) and one of the RCC; using RT-PCR with specific primers, we 
could find low levels of cadherin-4 transcript in five more cell lines. 
 P-cadherin was not detectable using Western blot in any of the cell lines. 
 Altogether, the RCC cell lines investigated as well as normal kidney 
displayed a complex pattern of cadherin expression.  It is already known that 
cadherin expression in kidney is highly structured, with differential expression in 
the various segments of the nephron.  For instance, the proximal convoluted tubule 
and the proximal straight tubule express N-cadherin, the thick ascending limb, the 
Chapter 2 
 
32 
distal convoluted tubule, and the collecting duct express E-cadherin, whereas the 
thin limb of the Henle loop coexpresses both molecules [3].  Based on in situ 
hybridization studies of the developing kidney, it is likely that cadherins-6 and -11 
also have a specific expression pattern in kidney.  For cadherin-6, the signal 
obtained with the Northern blot of normal kidneys was weak when compared to 
those of the cell lines.  This might indicate that in human adult kidney, cadherin-6 
expression is also restricted to one particular compartment of the nephron.  Indeed, 
in the rat developing kidney, cadherin-6 expression is restricted to the S-shaped 
body (the progenitor of, among others, the proximal tubule); no expression was 
found in the ureter or collecting duct [14].  In the mouse developing kidney, a 
marked cadherin-11 expression was found in the metanephric mesenchyme 
surrounding the developing nephron but not in the epithelial nephron [15,16].  
Based on the widespread expression of cadherin-11 in mesenchyme [15-17], one can 
expect that the signal obtained with normal kidney resulted from the expression by 
the stromal compartment. 
 It is tempting to relate the cadherin phenotype of RCC to the origin of these 
tumors along the nephron.  The widespread expression of N-cadherin (also found 
by others in RCC samples) supports the generally admitted proximal tubular origin 
of RCC.  However, the high proportion of tumors coexpressing N- and E-cadherins 
(up to 30% in our series) show that correlation between phenotype and tumor origin 
are not always straightforward.  In these cases, E-cadherin is probably aberrantly 
expressed by tumors originating from the proximal tubule.  Thus, E-cadherin 
expression would reflect perturbations of the differentiation process, similar to 
metaplastic processes seen in other carcinomas. 
 Although almost all combinations of cadherins were found in the 20 lines 
studied here, no coexpression of E-cadherin and cadherin-11 was observed.  This 
supports the current view that cadherin-11 is a mesenchymal marker, whereas 
E-cadherin is associated with epithelial differentiation.  Indeed, five of six lines 
expression E-cadherin have an epithelial phenotype (the sixth one having an 
intermediate phenotype), whereas the four lines with a clear cadherin-11 expression 
are fibroblastic.  Thus, expression of cadherin-11 may be related to reexpression of 
mesenchymal markers in RCC, similar to reexpression of vimentin [18]. 
 Since N-cadherin is expressed by almost all of the lines, it seems unlikely 
that N-cadherin expression is an important factor of RCC aggressiveness.  The 
same observation has been made in astrocytomas and glioblastomas [19].  Recently, 
no correlation between N-cadherin expression and grade was found in a series of 34 
RCCs [20].  No insight into the role of cadherin-6 in kidney carcinogenesis can be 
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inferred from our data.  Furthermore, the accurate assessment of the role of all of 
these cadherins in the loss of epithelial integrity during kidney tumor development 
awaits studies at the protein level and experimental evidence such as transfection 
or use of blocking antibodies. 
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Abstract 
 
During the progression of many cancers, cell-cell adhesion molecules, e.g., 
E-cadherin (EC), may be down-regulated. In a number of carcinomas, EC has been 
described as an independent prognostic variable. We have studied the expression of 
adhesion molecules participating in cadherin-catenin complexes in renal cell 
carcinoma (RCC) specimens. Expression of EC, catenins and p120cas protein was 
examined in frozen tissue of 90 RCC specimens by immunohistochemistry, and 
these molecules were evaluated for their significance as prognostic markers. 
Staining was scored as normal (homogeneously positive at cell-cell borders) or 
abnormal (heterogeneous or absent). A significant correlation between poor survival 
and decreased expression of alpha-, beta- or gamma-catenin was observed, whereas 
no association between survival and EC or p120cas expression was seen. Cox's 
proportional hazard regression analysis showed that in patients with pT1-3N0M0 
disease, reduced alpha-catenin expression correlated with poor survival, suggesting 
that alpha-catenin expression might be an independent prognostic indicator for 
patients of this group. 
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Introduction 
 
The clinical course of renal cell carcinoma (RCC) is unpredictable and only 
limited treatment modalities are available.  Pathological staging is the golden 
standard as prognostic indicator. However, within the group of low stage tumors 
(pT1-3, N0, M0), a significant percent of patients shows recurrence of disease after 
radical nephrectomy [1]. Several investigators have studied the value of possible 
prognostic indicators, e. g., grade of nuclear pleomorphism [2], morphometric 
analysis [3], DNA flowcytometry [4, 5], proliferation rate [6-9], p53 over expression 
[10, 11], expression of renal antigens [5], and specific genetic alterations [12-14]. 
Despite this intensive research, no clear marker has been identified that can 
distinguish patients at risk for the tumor recurrence within the pT1-3 group. 
Cadherins are a family of transmembrane glycoproteins mainly involved in 
homophilic and homotypic calcium-dependent intercellular adhesion interactions in 
tissues.  A number of cytoplasmic proteins (alpha-, beta-, gamma-catenin and 
p120cas) form non-covalent complexes with cadherins, linking to the cytoskelton, 
and regulate cadherin function.  Several lines of evidence indicate that in several 
tumor types cadherin mediated adhesiveness is critically important for epithelial 
integrity: e.g., decreased E-cadherin expression correlates with tumor invasiveness, 
metastatic potential, and poor survival of the patients [15].  Recently, Katagiri et al. 
[16] reported that normal E-cadherin expression in RCC was associated with good 
survival.  However, the number of tumors expressing E-cadherin was extremely 
low (less than 20 % ) when compare to other carcinoma (e.g. breast, colorectal, head 
and neck, prostate and bladder, approximately 60 to 100% [17]).  Another 
cadherins might prove a superior marker or, alternatively, cadherin complexed 
molecules may prove to be useful for prognostic staging. 
Since we have recently shown that RCC express a complex set of cadherins 
which all interact with catenins [18], we have investigated the expression of 
cadherin associated molecules, i.e., alpha-catenin, beta-catenin, gamma-catenin and 
p120cas by immunohistochemistry to evaluate whether any of these molecules 
maybe valuable as independent prognostic marker in RCC. 
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Materials and Methods 
Fresh frozen tissues of 90 patients with RCC who underwent nephrectomy at 
the University Hospital Nijmegen were studied.  The age of the patients at the 
time of surgery was 17 to 86 years (average 59.4) (Table 1). Follow-up ranged from 6 
to 105 months with an average of 42.4 months.  Additionally 12 specimen of 
normal renal tissues, obtained from an uninvolved portion of the removed kidney 
were investigated.  Histopathological evaluation was performed on hematoxylin 
and eosin stained sections and tumors were staged according to the pathological 
TNM classification [19].  Histological cell types were evaluated based on the 
modified classification after Murphy [20], i. e. clear cell, granular cell, 
tubulopapillary, sarcomatoid and mixed cell (composed of clear and granular cell). 
 
 
 
Table 1  Expression pattern for E-cadherin and cadherin associated proteins in 
RCC                          
   EC      alpha beta    gamma  p120cas 
   N A     N  A N  A   N   A N    A 
pT1-3N0M0 18  40    45  13   51  7   41  17 52   6 
pT4, N1-3  13  29    12  20   17  15   13  19 24   8  
  or M 
 p value 0.02     0.0002  0.0002   0.0053  0.0663 
 
clear cell 12  34    36  10 43   3   35  11 44    2 
granular cell 3   24     11  16 15  12   11  16 20    7 
mixed cell 5    7      7   5  7    5   6   6  9     3 
tubulopapillary 1    3      3   1  3    1   2   2  3     1 
sarcomatoid 0    1      0   1  0    1   0   1  0     1 
p valueb 0.616      0.073 0.035    0.090 0.276 
total  21  69    57  33 68   22  54  36 76   14 
 
EC: E-cadherin, alpha, beta and gamma: alpha-, beta- and gamma-catenin, respectively; N: normal 
expression, A: abnormal expression; p values were assessed by χ2 analysis (a) and Kruskal-Wallis test 
(b). 
 
Immunohistochemical staining 
Antibodies used were HECD-1 for E-cadherin (1/20, Takara), anti-beta-catenin 
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for beta-catenin and anti-pp120 for p120cas (1/400 and 1/200 respectively, 
Transduction Laboratories) and PG5.1 for plakoglobin (1/10, Progen Biotechnik 
GmbH).  For alpha-catenin staining, a polyclonal mouse antiserum was developed 
as previously described (Shimazui et al., 1996).  In addition to this, mouse 
monoclonal antibody RC3 was used to distinct proximal tubules in normal kidney 
[21].  
Serial sections of frozen tissues (4 um) were fixed in 3% paraformaldehyde and 
permeabilized with 0.2% triton X-100 in PBS. Immunohistochemistry was 
performed using biotinylated anti-mouse antibody (1/200) and streptavidin biotin 
peroxidase complex (1/100, Amersham).   The color reaction for sections was 
developed with 3,3'-diaminobenzidine tetrahydrochloride/0.03 % H2O2, 
counterstained with hematoxylin and mounted. 
 
Evaluation of immunohistochemical staining 
Tumor sections were scored by light microscope by three independent observers 
(TS, PPB, and ER) without knowledge of the stage and patients profile.   If the 
staining pattern in cancer cells was exclusively at cell-cell borders, the antigen 
expression was scored as normal.  If reactivity was absent, i.e., complete absence of 
immunoreactivity, or heterogeneous, i.e. when the tumor was composed of positive 
and negative areas, the antigen expression was scored as abnormal expression. In 
38 cases, in which the score with respect to the staining pattern of E-cadherin was 
not unanimous, E-cadherin western blot analysis was performed to confirm absence 
of E-cadherin expression.   
 
Western blot analysis 
Serial sections of fresh frozen tissue were lysed in SDS sample buffer. For each 
sample 25 μg of protein was separated on a 7% SDS-polyacrylamide gel and 
transferred onto nitrocellulose filters.   Antibodies used were anti E-cadherin 
(HECD1, 1/500) and anti α-catenin (polyvalent, 1/1000) as described above.  
Antibody binding was visualized using chemiluminescence (ECL, Amersham), 
according to the manufacture description. 
 
 
 
Statistical evaluation of clinico-pathological data 
To investigate whether a correlation between antigen expression and tumors 
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stage existed, the χ2 test was applied. The population was divided into low 
(pT1-3N0M0) and high stage (pT4, N1-3 or M1) patients.  Survival curves were 
constructed by the method of Kaplan and Meier. Statistical analyses for survival 
were calculated by Log rank test.  To evaluate the prognostic significance, Cox's 
proportional regression analysis was performed.  All the statistical procedures 
were supported by Statistical Analysis System (SAS).  Values of p<0.05 were 
considered significant. 
 
Results 
Immunohistochemical staining 
In all of normal kidney, epithelium of proximal tubules failed to express 
E-cadherin despite positive expression of RC3 (Fig. 1a and b).  In contrast, α-, 
β-catenin and p120cas were expressed at the cell-cell borders as well as the 
cytoplasm, albeit weak.  In addition, weak cytoplasmic staining was observed for 
γ-catenin. Cells of the thin limb of Henle's loop, distal tubules and collecting duct 
expressed E-cadherin, α-, β- and γ-catenin and p120cas at the cell-cell borders (Fig. 
2a-e). 
 
   
 
Fig. 1:  RC3 (a) and E-cadherin (b) staining in normal kidney.  Proximal tubules (P) which express 
RC3 fail to express E-cadherin. Original magnification x400. 
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In RCC, 21 of 90 tumors (37%) showed normal E-cadherin expression, whereas 
normal expression of α-, β-, γ-catenin and p120cas was observed in 63.3% (57/90), 
75.5% (68/90), 60.0% (54/90) and 84.4% (76/90), respectively (Table 1).   For the 69 
patients with abnormal expression of E-cadherin, absence of the expression was 
seen in the majority of cases (62/69), whereas absent expression of α-, β-, γ-catenin 
and p120cas was observed in very rare cases (1/69, 1/69, 17/69 and 1/69, 
respectively).   As an example, abnormal expression of E-cadherin staining and its 
corresponding α-catenin staining are shown in Fig. 3 (Fig. 3a-f). 
 
Fig. 2: E-cadherin (a), alpha- (b), beta- (c) and
gamma-catenin (d) and p120cas (e) staining in
normal kidney. Proximal tubular epithelial cells
fail to express E-cadherin, whereas they express
alpha-, beta- and gamma-catenin and p120cas at
the basolateral cell-cell borders. In distal tubules,
all the cell adhesion molecules, E-cadherin , alpha-,
beta-, and gamma-catenin and p120cas are
expressed at the cell-cell border. In both proximal
and distal tubules, luminal surface is devoid of the
staining. Original magnification x400. 
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Fig. 3: Aberrant expression of E-cadherin (a, b and c) and alpha-catenin staining (d, e and f) for same 
specimens. Renal cell carcinoma with heterogeneous expression of E-cadherin (a) expresses 
alpha-catenin heterogeneously (d). Renal cell carcinoma with absent expression of E-cadherin (b) is 
showing a conserved staining of alpha-catenin at the cell-cell border (e) whereas another tumor with 
absent E-cadherin immunoreactivity expresses alpha-catenin heterogeneously (f).Original 
magnification x400. 
 
Western blot analysis 
Western blot analysis was performed for 38 samples in which very weak 
homogenous E-cadherin expression seemed to be present. In 31 tumors no 
E-cadherin expression was observed, whereas all 31 tumors did express α-catenin.  
In 7 tumors, bands corresponding to both E-cadherin and α-catenin were visualized. 
In only one sample E-cadherin as well as α-catenin expression was absent (Fig. 4). 
 
 
Fig. 4: Western blot analysis using antibodies against E-cadherin (HECD-1) and α-catenin (mouse 
polyvalent serum) on renal cell carcinoma specimens (Twenty-five ug of extracted protein were loaded 
in each lane).  In only one case (#37), a 120 kDa band corresponding to E-cadherin is seen.  All the 
samples except for #85 are showing 102 kDa bands corresponding to alpha-catenin.    Ec: E-cadherin, 
a: alpha-catenin, A431: positive control expressing E-cadherin and alpha-catenin, derived from human 
epidermoid carcinoma. 
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Correlation between cadherin-catenin expression patterns and clinico-pathological 
parameters 
Significant correlation between expression of E-cadherin, α-, β- and γ-catenin 
and tumor stage was found, whereas no correlation existed for p120cas expression 
(p=0.02, p=0.0002, p=0.0002, p=0.0053 and p=0.0663, respectively).   In contrast, 
there was no significant correlation between histological cell type and expression of 
these molecules with an exception of β-catenin (p=0.035) (Table 1). 
Kaplan-Meier survival analysis showed no correlation between abnormal 
expression of E-cadherin or p120cas and patient survival (p>0.10; p>0.05, Fig 5A). 
In contrast, a significant correlation was observed between α-, β- and γ-catenin 
expression and survival (p<0.01, p<0.025 and p<0.01, respectively, Fig. 5B, C and 
D). 
Additional analysis of the pT1-3N0M0 patients revealed a significant 
correlation between survival and abnormal α-catenin expression (p<0.01, Fig.5E).  
None of the other investigated markers showed a significant correlation between 
survival and expression for this group. 
 
Cox's proportional hazard regression analysis 
Cox's proportional hazards model showed tumor stage to be the most powerful 
prognostic variable for the whole group studied (Table 2). None of the other markers 
studied carried any additional independent prognostic information.  
Within the group of pT1-3N0M0 disease patients, α-catenin expression was a 
significant independent prognostic marker (p=0.044, Table 3). 
 
 
Table 2   Cox's proportional hazard regression analysis for all patients  
   χ2  p value    risk ratio 
stage    23.8  0.0001  7.23 
E-cadherin  0.39  0.534  0.71 
alpha-catenin  1.01  0.316  1.56 
beta-catenin  3.46  0.063  0.34 
gamma-catenin  3.75  0.053  2.45 
p120cas   0.75  0.387  1.59 
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Table 3 Cox's proportional hazard regression analysis for the patients with 
pT1-3N0M0 disease 
   χ2  p value        risk ratio 
stage (pT)  2.721  0.099   3.19 
E-cadherin  0.140  0.708   0.73 
alpha-catenin  4.070  0.044*   5.03 
beta-catenin  0.362  0.548   0.53 
gamma-catenin  0.453   0.501   1.65 
p120cas   0.039   0.843   0.79 
       * alpha-catenin is a significant prognostic marker in this group 
 
 
Discussion  
The results of this study indicate that aberrant α-catenin expression 
significantly correlated with survival in pT1-3, N0, M0 patients (p<0.044 by Cox's 
proportional hazards model). Thus, immunohistochemical analysis using anti 
α-catenin antibodies may be used to identify high-risk patients.  As 45-65 % of 
patients with localized RCC (pT1-3, N0, M0) will develop a local recurrence or 
develop metastases after radical nephrectomy [2, 22] and prognosis of these 
patients is very poor, with a mortality of approximately 74 % at one year after 
tumor recurrence [22], accurate identification of high risk patients is very relevant. 
Despite intensive efforts, no additional prognostic marker has been identified to 
stratify patients into high and low risk patients. The histopathological grading 
according to World Health Organization (WHO) criteria [23] describes nuclear 
atypia.  However, this grading system remains controversial because of 
interobserver variability, despite the modification to simplify the grading criteria 
[24].  Flowcytometry studies have shown that aneuploid tumors formed the worst 
prognostic group for stage IV patients [4, 5], but no indication of the prognostic 
significance of ploidy in pT1-3 disease was observed. In addition to flowcytometric 
studies, studies concerning p53 over expression [11], genetic alterations on 
chromosomes 3p and 17p [13, 14], silver stained nuclear organizer region [25, 26] 
and proliferation rate assessed by Ki-67 [7] have been performed.   With the 
exception of AgNOR in pT1-2 stage patients [26], none of these markers was 
identified as prognostic relevance. 
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Fig. 5: Survival curves constructed by method of 
Kaplan and Meier according to E-cadherin 
staining (A), alpha-catenin staining (B), 
beta-catenin staining (C) and gamma-catenin 
staining (D) for all patients. E-cadherin staining 
does not correlate with survival of the patients 
whereas alpha-, beta- and gamma-catenin 
staining correlate significantly (p<0.01, p<0.025 
and p<0.01, respectively). For the patients with 
pT1-3N0M0, decreased alpha-catenin staining 
significantly correlates with poor survival (E, 
p<0.01). 
 
A correlation between E-cadherin expression and tumor aggressiveness was 
found for a number of carcinomas, i. e., bladder, breast, head and neck, prostate, 
stomach [15] and kidney [16]. In the present study, 69/90 tumors (77 %) failed to 
express E-cadherin at the cell-cell borders, similar to the study by Katagiri et al. 
[16] and E-cadherin expression also correlated with tumor stage. However, no 
correlation with survival was found. This may be explained by the paucity of the 
number of patients. Thus, in this study E-cadherin expression was not a prognostic 
marker in RCC.  The high percentage of E-cadherin-negative RCC in comparison 
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to other tumor types [17] can be explained by the origin of RCC: renal proximal 
tubular epithelial cells from which majority of RCC originate [21, 27, 28] failed to 
express E-cadherin. These cells have been shown to express N-cadherin [29] and 
cadherin 6 (Shimazui et al., manuscript in preparation), i. e. other cadherins are 
involved in the cell adhesion complex in proximal tubular epithelial cells. Therefore, 
E-cadherin expression of RCC should be viewed as up-regulation (or aberrant 
expression), and absence of E-cadherin should not be interpreted as loss of a 
molecule crucial to the cadherin-catenin complex of these cells. Most likely 
N-cadherin and cadherin 6 function as the major cadherins in RCC, but the 
significance of loss of these cadherins for RCC is still unclear. Based on studies in 
RCC cell lines N-cadherin expression did not seem to be an important factor of 
tumor aggressiveness [18], similar to observations in astrocytoma and glioblastoma 
[30]. In addition, no correlation between N-cadherin expression and grade was 
found in a series of 34 RCCs [31]. 
The prognostic value of beta- and gamma-catenin was lower than alpha-catenin. 
This may be explained by their role in the cadherin-catenin complex: both beta- and 
gamma-catenin are able to bind directly to cadherin, whereas alpha-catenin plays 
an essential role in the linkage of the beta/ gamma-catenin-cadherin complex to the 
cytoskelton. Therefore, a functional complex can only be present with normal 
alpha-catenin expression, whereas e.g., aberrant expression of either beta-catenin 
or gamma-catenin does not necessary lead to a non-functional complex. 
Expression of p120cas, another group of proteins associated with the 
catenin-cadherin complex, had no prognostic value in RCC. p120cas are tyrosine 
kinase substrates consisting of at least four putative isoforms  [32].  Recently 
Daniel et al. [33] showed p120cas interaction with E-cadherin but not with 
alpha-catenin. By immunohistochemistry, using a p120cas antibody, normal 
expression of p120cas was more frequent than normal expression of catenins. One 
may speculate that one isoform of p120cas can be expressed at cell-cell borders 
independent of cadherin-catenin complexes.  This unbalanced expression of 
p120cas isoforms in human carcinomas may influence the cadherin-catenin complex 
and contribute to malignant or metastatic cell phenotypes [32]. However, the 
precise function of p120cas in the cadherin complex is not yet understood.  
Our observation that a significant correlation exists between alpha-catenin 
expression and survival in patients with pT1-3N0M0 disease independent of tumor 
stage, indicates that alpha-catenin expression is an independent prognostic marker 
for these patients.  A prospective study is warranted to confirm and extend our 
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results.  Additional studies are also required to investigate the role of cadherin in 
RCC, e. g., study of N-cadherin and cadherin 6 expression using specific antibodies.  
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Abstract 
 
In many carcinomas, E-cadherin is considered to be a prognostic marker for 
patient survivals, and its decreased expression is associated with metastatic disease. 
Among renal cell carcinomas (RCCs), however, only 20% of tumors express 
E-cadherin, whereas a much higher percentage express other cadherins, e.g., 
N-cadherin and cadherin-6 (T. Shimazui et al, Cancer Res., 56: 3234-3237, 1996). 
Among these cadherins expressed in RCCs, cadherin-6 has been identified as a 
major cadherin in the renal proximal tubules and in the tumors themselves. Hence, 
we have investigated the relationship between prognosis and cadherin-6 expression 
in tumor cells in 43 patients with RCC. Expression of cadherin-6, E-cadherin, and 
alpha-catenin was detected immunohistochemically and evaluated microscopically 
as normal, heterogeneous, or absent. Normal, heterogeneous, and absent expression 
of cadherin-6 were observed in 19, 16, and 8 of 43 cases, respectively. Coexpression 
of E-cadherin and cadherin-6 was detected in only 10 cases. Among 30 tumors in 
which E-cadherin expression was absent, 24 expressed cadherin-6. In addition, the 
expression pattern of alpha-catenin correlated more highly with that of cadherin-6 
than it did with E-cadherin (P = 0.0003 versus 0.025). In survival analyses, 
aberrant expression of cadherin-6 correlated with poor survivals both among all 
patients (P = 0.0009) and in those with E-cadherin-absent RCC (P = 0.0008). These 
results suggest that cadherin-6 is a major cadherin playing an essential role in 
cell-cell adhesion in E-cadherin-absent RCC. 
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Introduction 
In renal cell carcinomas (RCCs), the existence of a distant metastasis is the 
most powerful prognostic factor for predicting patient survival [1-4].  Although the 
metastatic cascade from the primary tumor to a distant organ still remains 
controversial, loss of cell-cell adhesion is considered to play an important role as a 
first step of this cascade [5].  In many carcinomas, E-cadherin functions to preserve 
epithelial integrity, and decreased expression of this molecule is associated with the 
presence of metastatic disease and with poor prognosis of patients [6-8]. 
Although Katagiri et al. [9] have reported that normal expression of E-cadherin 
has a prognostic value in RCC, E-cadherin is expressed in no more than 
approximately 20% of RCCs [9,10].  And in fact, the majority of RCCs are thought 
to originate from the epithelia in the renal proximal tubules in which E-cadherin is 
not expressed.  We have previously reported that RCC cell lines expressed mRNA 
of several cadherins, such as E-cadherin, N-cadherin and cadherin-6 [10], with the 
latter two expressed more frequently than E-cadherin.  Nouwen et al. [11] observed 
N-cadherin expression in the proximal tubular epithelia of normal kidneys.  In our 
study on RCC cell lines, however, we detected mRNA expressions of N-cadherin in 
all of the cell lines observed, and these expressions did not seem to correlate with 
cellular morphology [10]. Cadherin-6 was originally isolated from a hepatocellular 
carcinoma cell line lacking E- and P-cadherin, and it was shown that normal kidney 
and RCC cell lines expressed cadherin-6 mRNA [12] that demonstrated 97% 
homology with the cDNA of rat K-cadherin [13].  Hence we hypothesized that 
cadherin-6, rather than N-cadherin, might be an integral molecule in the cell-cell 
adhesion in RCC.  In this study we use a newly developed anti-cadherin-6 antibody 
to investigate the expression pattern and the localization of cadherin-6 in RCC.  In 
addition, we analyze the prognostic value of cadherin-6 in the paticular case of 
patients with E-cadherin-absent RCC. 
 
 
Materials and Methods 
Forty-three snap-frozen specimens obtained from patients with RCC who 
underwent nephrectomies at the University Hospital Nijmegen were studied. 
Details of the patient profiles and follow-up investigations are shown in Table 1.  
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Table 1  Patient characteristics and treatment
pathological stage  Immunostainingprognosis
case age sex grade pT pN M pV metastasis treatment Cd6 Ec a month A/D
1 44 F 3 3b 1 1 1 lung,bone Nx H (-) (+) 8 D
2 17 M 3 3 3 1 0 lung,mediastinum Nx,LND,IL2 H (-) H 68 D
3 57 M 2 2 0 0 0 Nx H H H 72 D
4 42 M 3 4 0 1 1 lung Nx,IFN,Cx H (-) H 18 D
5 77 F 2 3b 0 0 1 Nx,LND (+) (+) (+) 15 A
6 63 M 2 2 0 0 0 Nx (+) (-) (+) 84 A
7 60 F 2 3b 0 1 1 lung NX,IFN,RT H (-) (+) 25 D
8 61 M 1 2 0 0 0 Nx (+) (-) (+) 74 A
9 67 M 2 3b 1 1 0 adrenal gl Nx (+) (-) (+) 69 A
10 66 F 2 4 0 1 1 ileocecal Nx,colectomy H (-) (+) 7 D
11 57 F 1 2 0 0 0 Nx (-) (-) (+) 82 A
12 27 F 1 3a 1 1 1 ovary,liver,bone Nx,LND,IFN,RT (-) H H 5 D
13 65 M 2 3b 0 0 1 Nx,Cx H (-) (+) 68 A
14 47 M 1 2 0 0 0 Nx (+) (-) (+) 77 A
15 61 M 2 3b x 0 0 Nx,LND,IFN H (-) H 9 D
16 46 M 1 3a x 1 0 bone Nx,IFN (+) (-) H 66 A
17 35 F 3 3b 0 0 1 Nx,LND (-) (+) (+) 60 A
18 74 M 1 2 0 0 0 Nx (+) (+) (+) 66 A
19 67 M 2 3b x 0 2 Nx,IVC (-) (-) H 65 D
20 54 M 2 2 0 0 0 Nx H (+) (+) 60 A
21 56 M 2 3b 1 1 1 lung,bone Nx,pneumox,RT H (-) H 8 D
22 69 F 1 2 0 0 0 Nx (+) (-) (+) 67 A
23 52 M 1 3a 0 0 0 Nx (+) (-) (+) 60 A
24 68 M 3 3b 0 1 2 lung,bone Nx,IVC,pneumox H (-) H 4 D
25 48 M 1 2 0 0 0 Nx,LND (+) (+) (+) 58 A
26 65 M 2 2 0 0 0 Nx(partial) (-) (-) H 24 D
27 80 F 2 2 x 0 0 Nx (+) (-) (+) 64 A
28 47 M 1 3a 0 0 0 Nx H (+) (+) 56 A
29 46 M 2 3a 0 1 0 pancreas,kidney Nx,LND,IL2,IFN H (-) H 30 D
30 80 M 2 3a 0 0 0 Nx H (-) H 28 D
31 69 M 2 3b 3 0 1 Nx,LND (-) (-) H 10 A
32 55 M 2 3a 0 0 0 Nx,LND (+) (+) (+) 61 A
33 59 M 2 2 1 1 0 bone Nx,RT (+) (+) (+) 53 D
34 25 F 2 2 0 0 0 Nx (+) (-) (+) 42 A
35 66 M 2 2 0 0 0 Nx,LND H (+) (+) 34 D
36 62 F 2 3b 0 0 1 Nx,LND (+) (-) (+) 42 A
37 28 F 2 2 0 0 0 Nx,LND (-) (+) (+) 21 A
38 49 M 2 3a 1 1 1 lung Nx,LND,RT,IL2,IFN H (-) H 13 D
39 55 M 1 2 0 0 0 Nx,LND (+) (-) (+) 36 A
40 62 F 2 3b 0 1 1 lung Nx (-) (-) H 18 A
41 51 M 2 3a 0 0 0 Nx,LND (+) (-) (+) 29 A
42 72 M 1 3b 0 0 2 Nx,IVC (+) (-) (+) 22 A
43 73 F 2 3c 0 0 2 Nx,IVC (+) (+) (+) 12 A
pT, primary tumor; pN, regional lymph nodes; M, distant metastasis; pV, venous invasion
Nx, nephrectomy; LND, lymph node dissection; IFN, interferon-alpha; RT, irradiation;
pneumox, pneumonectomy
Cd6, cadherin-6; Ec, E-cadherin; a, a-catenin; (+), normal; (-), absent; H, heterogeneous
A, alive; D, dead.
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Age distribution ranged from 17 to 80 years, and the average age at the time of 
surgery was 56.0 years.  Histological evaluations were performed on 
hematoxylin-eosin sections.  The tumors were pathologically staged and were 
graded according to TNM classification [14]. Four normal kidney samples were also 
obtained from non-cancerous areas of nephrected kidneys. 
Serial frozen sections, 4-μm thick, were immunohistochemically stained using 
HECD-1 (Takara, Japan), anti-α-catenin mouse serum (8), and 2B6-D8 for 
E-cadherin, α-catenin, and cadherin-6, respectively.  2B6-D8 was newly developed 
as a mouse monoclonal antibody against the GST fusion extracellular domain of 
human cadherin-6 as follows.  Briefly, a 1233 bp nucleotide fragment (nucleotides 
323 to 1555 corresponding to human cadherin-6 cDNA) was generated using PCR 
and was cloned into the RpR265 vector.  The GST fusion protein was purified in an 
affinity column and used as an immunogen.  Female balb/c mice were immunized 
against the purified protein and after 3rd boost spleen cells were fused with SP2/0 
mouse myeloma cells.  Hybridomas were screened and then the 2B6-D8 clone was 
revealed as a specific clone producing a monoclonal antibody against cadherin-6, 
which recognized a single 125 kDa band comigrating with cadherin-6 on western 
blot (Fig. 1a).  Immunostaining was also carried out according to our previous 
procedure [8]. Immunohistochemically, 2B6-D8 demonstrated cell-cell border 
staining in the SKRC-33 cell line that expressed cadherin-6 alone [10] (Fig. 1b).  In 
addition, a mouse monoclonal antibody, RC-3, was used to distinguish renal 
proximal tubules as described previously [15]. 
Statistical analyses were performed to compare cadherin-6 expression with 
pathological parameters in restricted patients with E-cadherin-absent RCC.  The 
correlation between cadherin-6 and tumor stage and grade were evaluated by χ2 
test.  Survival curves were constructed by the Kaplan-Meier method, and the 
differences in survival were assessed by the Log-rank test.  The clinical relevancy 
of these molecules was analyzed by Cox’s proportional hazard model. 
Protein expressions on tumor sections were evaluated by light microscope.  If 
the staining pattern in cancer cells was exclusively at cell-cell borders, the antigen 
expression was scored as normal.  If reactivity was absent (i. e., if there was a 
complete absence of immunoreactivity), or heterogeneous (i. e., if the tumor was 
composed of positive and negative areas), antigen expression was scored as 
abnormal.  
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Fig. 1: Cadherin-6 expression in a renal cell carcinoma cell line.  a: Western blot analysis shows that 
the SKRC-33 renal cell carcinoma cell line expressed cadherin-6 (125 KDa) and α-catenin (105 KDa), 
but not E-cadherin.  b: Cadherin-6 expression is restricted at the cell-cell contact site by 
imunofluorescence staining using a monoclonal antibody 2B6-D8. 
 
 
 
 
Results 
Expression of cell adhesion molecules in the normal kidney. 
E-cadherin expression was restricted in distal tubules through collecting 
tubules, whereas cadherin-6 was expressed in proximal tubules and Henle’s thin 
loop.  E-cadherin expression was seen at all lateral cell-cell contact sites with the 
exception of the basal membrane.  On the other hand, cadherin-6 expression was 
located at the basolateral membranes along with α-catenin expression (Fig. 2a-d). 
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Fig. 2: Expression of Cadherin and catenin in the normal kidney.  Renal proximal tubules stained by 
RC-3 (d) express cadherin-6 (a) and α-catenin (c) at the basolateral site of the epithelium, but do not 
express E-cadherin (b).  E-cadherin is expressed at the cell-cell border in the renal distal tubular 
epithelia (b). 
   
 
 
Expression of cell adhesion molecules in RCC. 
Details of the expression of each molecule in RCC specimens are summarized in 
Table 1.  Only 11 tumors showed normal expression of E-cadherin at the cell-cell 
borders, whereas, in 30 out of 32 E-cadherin aberrant tumors expression of 
E-cadherin was completely absent. Normal, heterogeneous, and absent expression 
of cadherin-6 were observed in 19, 16, and 8 out of 43 cases, respectively.  
Co-expression of E-cadherin and cadherin-6 was detected in 10 cases (Fig. 3c and 
3d).  Out of 30 tumors in which E-cadherin expression was absent, 14 showed 
normal and 16 abnormal expression of cadherin-6 (Table 2, Fig. 3a, 3b, 3e and 3f).  
In addition, expression of α-catenin significantly correlated with that of cadherin-6 
in the E-cadherin-absent group (χ2=11.8, p=0.0006). 
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Fig. 3: Several combinations of expression pattern between cadherin-6 and E-cadherin are observed in 
RCC specimens.  #6 RCC shows normal cell-cell border staining of cadherin-6 (a) with absent 
E-cadherin (b).  In #32, both cadherin-6 (c) and E-cadherin (d) are homogeneously expressed at the 
cell-cell border.  Heterogeneous cadherin-6 (e) staining is observed in #49, whereas E-cadherin (f) is 
absent. 
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Table 2   Correlation between E-cadherin and cadherin-6 in RCC 
 
    E-cadherin 
cadherin-6  normal heterogeneous absent  total 
normal   6  0 13  19 
heterogeneous  3  1 12  16 
absent   2  1 5  8 
total   11  2 30  43 
 
 
 
 
Table 3 Cox’s proportional hazard model in the patients with E-cadherin-absent 
RCC 
 
 values   χ2  p value    hazard ratio 
 cadherin-6  4.93  0.027  12.66 
 stage   0.57  0.45  3.46 
 nodal status  0.037  0.85  0.860 
 distant metastasis 0.012  0.91  0.831 
 grade   0.16  0.69  1.39 
 
 
  
Statistical analyses in the subgroup with E-cadherin-absent RCC. 
The expression pattern of cadherin-6 correlated with tumor stage and grade 
(χ2=7.30, p=0.007 and χ2=10.15, p=0.006) independent of E-cadherin expression.  
In the survival analyses, although prognosis of the patients with normal expression 
of E-cadherin was better than that of those with abnormal expression, the 
difference was not statistically significant (p=0.265) (Fig. 4a).  For the restricted 
patients with absent E-cadherin expression, expression of cadherin-6 strongly 
correlated with patient survival (p=0.0008) (Fig 3b).   Additionally, Cox’s 
proportional regression analysis revealed that the expression pattern of cadherin-6 
had a higher risk ratio in prognosis than the pathological parameters for patients 
with RCC (Table 3). 
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Fig. 4: Survival curves demonstrate no significant difference in survival between patients with 
tumors showing normal and abnormal expression of E-cadherin (a: p=0.265).  Among patients with 
E-cadherin-absent tumors, the survival of those with tumors showing abnormal cadherin-6 expression 
was significantly lower than that of those showing normal cadherin-6 expression (b: p=0.0008). 
 
 
Discussion 
It is generally considered that E-cadherin functions as an invasion suppressor 
gene and correlates with the survival of patients with many different carcinomas, 
e.g., bladder tumors and prostate, breast, skin, colon, and gastric cancers [5-7,16,17].  
Katagiri et al. [9] have reported that normal E-cadherin expression is associated 
with better survival of patients with RCC.  However, it has been shown that most 
RCCs (70-80%) demonstrated absent E-cadherin expression and only 20% exhibited 
normal E-cadherin expression as compared with the normal expression rate of 
E-cadherin in other carcinomas [9, 10].  As mentioned above, this can probably be 
attributed to the fact that the renal proximal tubules, which are presumably an 
origine of RCC, do not express E-cadherin.  Although N-cadherin has been 
identified as one of the cell adhesion proteins expressed in the renal proximal 
tubules [11], Tani et al. [18] have demonstrated that E- and N-cadherin expression 
do not correlate with tumor grade in RCC.  Thus, it remains unclear whether or 
not aberrant expression of the cadherin molecules expressed in RCC is associated 
with poor prognosis of patients.  Recently, Paul et al. [19] demonstrated that 
cadherin-6 is expressed in renal proximal tubular epithelia, and that RCC and its 
aberrant expression seem to correlate with dedifferentiation and progression of 
RCC.  In this study, we therefore extended their research to focus on the 
correlation between the expression pattern of cadherin-6 and the prognosis of 
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patients with RCC. 
When looking at the expression of each cadherin, co-expression of E-cadherin 
and cadherin-6 was observed in only 10 of 43 tumors.  This may be explained by 
up-regulation of E-cadherin during the carcinogenesis of RCC arising from renal 
proximal tubules.  Another explanation is that some RCCs might be derived from 
the segment of the nephron that co-expresses both E-cadherin and cadherin-6.     
Even if the up-regulation of E-cadherin expression is an aberrant phenomenon in 
RCC, its homogenous cell border expression seems to be associated with less 
metastatic disease and better prognosis of patients [9]. 
For this reason, we focused on cadherin-6 expression in the subgroup with 
E-cadherin-absent tumors.  In this group, aberrant cadherin-6 expression 
correlated with distant metastatic disease [10/16] whereas normal cadherin-6 
expression did not [2/14].  This finding suggested that cadherin-6 acted as a 
metastasis suppressor molecule in RCC.  Expression of cadherin-6 significantly 
decreased with an increase of tumor grade and stage much as in the study by Paul 
et al. [19].  These relationships between cadherin-6 and pathological parameters 
were highly pronounced in the E-cadherin-absent cancer group.  
Cadherin-6 expression significantly correlated with α-catenin expression in our 
series.  This suggested that cadherin-6 may have been forming a functional cell 
adhesion complex with α-catenin in RCC, as in our previous in vitro investigation 
[10].  Paul et al. [19] revealed in an immunoprecipitation study that α- and 
β-catenin are coprecipitated with cadherin-6 in RCC cell lines, suggesting that the 
binding to catenins is likely to be important for proper functioning of cadherin-6.  
On the other hand, some tumors expressed neither E-cadherin nor cadherin-6, but 
did express α-catenin (i.e., numbers 11, 19, 26, 31, and 40).  This fact might 
indicate that other cadherins, e.g., N-cadherin, expressed and formed a cell 
adhesion complex with α-catenin [20].  Further immunohistochemical studies will 
be needed to clarify the diversity of cadherin expression in RCC.   
In conclusion, we revealed that cadherin-6 is specifically expressed in the 
epithelial cells of renal proximal tubules and is retained in most RCCs.  Thus, 
cadherin-6 could be considered one of the major cadherins expressed in RCC, and its 
expression could be considered to have greater prognostic value than tumor stage or 
grade in this disease.  These immunohistochemical observations constitute the 
first report on the prognostic value of cadherin-6 for patients with RCC.   
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Abstract 
 
OBJECTIVES: Cell-cell adhesion mediated by cadherins is tight and stable and 
preserves tissue integrity. However, during tissue remodeling, e.g., development, 
adhesion may be modified for morphogenic movement. Similarly, during 
carcinogenesis, cell-cell adhesion might alter leading to a more aggressive 
phenotype. Here we describe cadherin expression patterns in developing, adult, and 
neoplastic kidney.  
METHODS: Fetal kidneys were obtained from voluntary terminations of pregnancy 
and 43 renal cell carcinomas (RCC) and normal kidneys were obtained at 
nephrectomy. Frozen sections of these specimens were stained 
immunohistochemically using antibodies against E-cadherin (ECD), cadherin-6 
(CAD6) and alpha-catenin (alpha-cat).  
RESULTS: CAD6 was expressed in lower and middle limbs of the S-shaped bodies, 
structures that will develop into renal proximal tubules, which also express CAD6. 
Similarly, ECD was expressed in the upper limb of S-shaped bodies, structures 
which will develop into distal and collecting tubules which also express ECD. 
Twenty-four out of 43 RCC (55.8%) displayed a CAD6 (+)/ECD (-)/alpha-cat (+) 
phenotype. The other RCC had a CAD6 (+)/ECD (+)/alpha-cat (+) phenotype (10/43, 
23.2%), CAD6 (-)/ECD (+)/alpha-cat (+) phenotype (3/43, 7.0%) or CAD6 (-)/ECD 
(-)/alpha-cat (+) phenotype (6/43, 14.0%), respectively. On the other hand, normal, 
heterogeneous, or absent expression of CAD6 was seen in 19, 15, and 9 tumors, 
whereas in 11, 2, and 30 tumors, respectively, ECD expression was seen. Survival 
curves showed that abnormal CAD6 expression correlated with a poor prognosis 
rather than abnormal ECD expression.  
CONCLUSIONS: The combination of cadherin expression appeared to be fixed 
relatively early during kidney organogenesis. Since almost all RCC originate from 
proximal tubular epithelial cells (CAD6 (+)/ECD (-)/alpha-cat (+)), only 55. 8% of 
RCC retained the original cadherin phenotype. Alterations in expression of these 
molecules may be a reflection of the degree of dedifferentiation from the primary 
organ. In addition, scoring of expression patterns including heterogeneous 
expression could be a useful tool to estimate the malignancy potential of the tumor. 
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Introduction  
The cadherin family of molecules is a large family of transmembrane cell-cell 
adhesion molecules which preserve the tissue integrity in a homophilic, homotypic 
manner.  These molecules play an important role in specific cell-cell adhesion, 
particularly in all processes involving tissue remodeling, e.g., cell-proliferation, 
differentiation, morphogenesis and maintenance of multicellular structures.  
Cadherin molecules are generally associated with catenins, i.e., α-, β- and γ-catenin, 
which link cadherin to the actin-based cytoskelton [1-3].  Cadherin mediated 
cell-cell contact is tight and stable but during tissue remodeling adhesion should be 
modified to allow morphogenic movement. Therefore cadherin-mediated cell-cell 
adhesion might alter during organ development.  Similarly, during tumor 
evolution, occurrence of tumor cells with altered cell-cell adhesion properties can 
lead to a more aggressive (metastatic) phenotype.  At the onset of kidney 
morphogenesis, only two tissue compartments can be distinguished 
morphologically: the nephrogenic mesenchyme and the ureter epithelium. 
Differentiation requires their interaction, and as a result nephrogenic mesenchymal 
cells are induced to become nephrogenic vesicles which contact terminal ampullae of 
the ureter epithelium.  The nephrogenic vesicles will eventually grow out to 
become the proximal nephron segments whereas the terminal ampullae will develop 
into the distal nephron segments and collecting duct system. During this process 
immense tissue remodeling occurs. 
The major epithelial cell adhesion molecule is E-cadherin, which is expressed in 
the majority of epithelial cells where it acts to preserve epithelial integrity. However, 
in adult kidney proximal tubular epithelial cells do not express E-cadherin.  Only 
cells of Bowman's capsule, the thin limb of Henle's loop, distal and collecting 
tubules express E-cadherin, whereas N-cadherin, which is predominantly expressed 
in neural cells, is present in proximal tubules [4].  Renal cell carcinoma (RCC), 
which comprises 90% of renal tumors, originates from proximal tubular cells.  In a 
previous study we have described the frequent expression of cadherin-6 in RCC cell 
lines at the mRNA level [5].  This cadherin-6 is the human homologue of rat 
K-cadherin [6], expressed in normal kidney and in RCC cell lines [5,7].  In contrast, 
N-cadherin mRNA was expressed in all RCC cell lines examined.  Additionally, we 
have observed α-catenin expression at the cell-cell borders in all nephron segments 
of the adult kidney [8].  This suggests the presence of cadherin-catenin complexes 
as functional cell adhesion complexes.  Thus, we hypothesized that certain critical 
cadherins, e.g., E-cadherin and cadherin-6, might play an important role during the 
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malignant transformation of renal tubular epithelial cells and during kidney 
development.  In this study, we have focused our attention on the alterations of 
these cadherin complexes during kidney development and in the neoplastic kidney 
tissue.  
 
 
Materials and methods 
Normal kidney and RCC specimens.  
Adult human kidney and 43 RCC specimens were obtained at nephrectomy 
at the Academic Hospital Nijmegen.  Histological evaluations were performed on H 
& E sections.  The histological subtype and pathological stage of the tumors were 
determined according to the WHO classification system [9] and TNM classification 
[10].  Patient follow-up periods were ranged between 10 and 84 months after 
nephrectomy.  Human fetal kidney specimens of 14 and 19 weeks gestation, as 
estimated from body length measurements were obtained from voluntary 
termination of pregnancy.  Tissue was snap-frozen in liquid nitrogen and stored at 
-70oC until use.  
 
Antibodies 
Antibodies used in this study were as follows: Monoclonal antibody (mAb) 
HECD-1 (Takara, Japan) for the detection of E-cadherin and a mouse polyclonal 
anti serum against a GST-human α-catenin fusion protein (Μα1) as described 
previously [11].  For cadherin-6, we have developed an anti-human cadherin-6 
mouse monoclonal antibody (clone 2B6).  Briefly, the purified GST fusion protein 
corresponding to the amino acid sequence 69-480 (nucleotide 363 to 1559) of human 
cadherin-6 was used as immunogen. Female BALB/c mice were immunized with 50 
μg protein in Freunds' complete adjuvant.  Subsequently animals were boosted 
with 50 μg protein in Freunds incomplete adjuvant.  After the fourth boost, 
splenocytes were harvested and fused with SP2/0 cells according to general 
hybridoma technology. Hybridoma cultures were tested by ELISA for the presence 
of cells producing mouse Ig reactive with cadherin-6. Supernatant of positive 
cultures was tested on frozen tissue sections and subcloned.  Western blot analyses 
was performed to confirm the mAb specificity, i.e., clone 2B6 recognized a single 
band of 120 kD, corresponding to cadherin-6. In addition, mouse mAb RC3 was used 
to delineate renal proximal tubules [12].  
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Immunohistochemical staining: 
Four μm serial frozen sections were stained using HECD-1 (diluted 1/20), 2B6 
(diluted 1/500) and Μα1 (diluted 1/500) as primary antibody, followed by 
biotinylated anti mouse antibody (used 1/200) (Amersham) and streptavidin biotin 
peroxidase complex (SABC) (used 1/100) (Amersham).  The sections were 
developed with 3,3'-diaminobenzidine tetrahydrochloride, containing 0.03% 
hydrogen peroxide and counterstained with hematoxylin. Evaluation of cadherin 
and catenin expression in developing kidneys and RCC.  
In fetal kidney, morphologically defined structures, i.e., the renal vesicles, 
S-shape bodies and capillary loop stage of the developing nephron were studied. 
Expression of cadherins and catenin in these structures were evaluated and scored 
as positive or negative. 
To evaluate the degree of dedifferentiation of RCC from normal kidney, 
expression of cadherin or catenin was scored as positive or negative, irrespective of 
homogeneity.  I.e., homogeneous and heterogeneous staining at the cell-cell contact 
site was scored as positive.  For clinico-pathological and survival analyses, 
expression pattern of cadherin or catenin was scored as normal, heterogeneous, or 
absent according to our previous paper [13].  Correlations between expression 
pattern of these molecules and pathological parameters were evaluated using χ2 
test.  In addition Kaplan-Meier survival curves according to cadherin expression 
pattern were statistically analyzed using log-rank test as previously reported [13]. 
 
 
Results 
Cadherin and α-catenin expression in fetal kidney 
In renal vesicles no E-cadherin expression was detected.  In contrast, strong 
expression of E-cadherin was observed in terminal ampullae from which all distal 
nephron elements evolve (Fig. 1A).  Renal vesicles (induced nephrogenic blastemal 
cells) expressed cadherin-6 (Fig. 1B).  In S-shaped bodies E-cadherin expression 
was restricted to the upper limb, i.e., to the progenitor cells of distal tubular 
epithelium (Fig. 1C), whereas cadherin-6 was expressed by cells in the middle limb 
of the S shaped bodies, i.e. expressed in progenitor cells of the proximal tubular 
epithelium (Fig. 1B).  At the capillary loop stage the developing renal proximal 
tubular epithelium, expressing RC3 (Fig. 1E), expressed cadherin-6 (Fig. 1F).  In 
contrast, developing renal distal tubules expressed E-cadherin only (Fig. 1G).  No 
dynamic changes were observed for α-catenin expression: α-catenin was expressed 
Chapter 5
 
72 
in induced nephrogenic blastemal cells, the first recognizable morphological 
structure known to evolve into the proximal part of the nephron, and in terminal 
ampullae, which gives rise to the more distal nephron segments, and in all 
developing nephron segments throughout nephron development (Fig. 1D and H).  
Figure 2 shows a schematic representation of cadherin and catenin expression 
during kidney development.  
 
Cadherin and α-catenin expression in adult kidney 
In normal adult kidney, E-cadherin expression was observed in distal tubules 
and collecting ducts (Fig. 3A).  In contrast, cadherin-6 expression was restricted to 
proximal tubular epithelium (Fig. 3B). Cadherin-6 was located at epithelial cell-cell 
contact sites but also basolaterally (Fig. 3B).  The identity of the proximal tubular 
cells was confirmed with mAb RC3 (Fig. 3D).  Expression of α-catenin was 
observed in all segments of the nephron (Fig. 3C) as previously reported [8]. 
 
Cadherin and catenin expression in RCC 
E-Cadherin and cadherin-6 expression patterns and the respective histological 
type of RCC are presented in Table 1. Four different phenotypes (Fig. 2) were 
observed: Cadherin-6+/E-cadherin- (24/43), Cadherin-6+/E-cadherin+ (10/43), 
cadherin-6-/E-cadherin+ (3/43) and cadherin-6-/E-cadherin- (6/43) (Fig. 2).  Thus 
expression of cadherin-6 was found in 34 out of 43 samples, whereas E-cadherin 
expression was found in 13 out of 43 tumors. Figure 4 shows representative 
examples of cadherin-6+/E-cadherin- RCC (Fig. 4A and B), and of RCC 
co-expressing E-cadherin and cadherin-6 (Fig. 4C and D).  No significant 
correlation was found between cadherin expression patterns and the histological 
type of RCC (Table 1).  All tumors examined expressed α-catenin, including the 6 
tumors in which neither E-cadherin nor cadherin-6 was detectable.  It is of note 
that in these tumors α-catenin expression appeared heterogeneous. 
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Fig. 1: Immunohistochemical staining of human fetal kidney tissue. In the renal vesicle stage and 
S-shape body stage of nephron development, terminal ampullae (TA (A)) express E-cadherin, but renal 
vesicles (arrows (A)) and S shaped bodies (SSB (C)) are E-cadherin-negative. Cadherin-6 is expressed 
in renal vesicles (RV) and in the lower up to a part of the upper limb of the S shape body (SSB (arrows)), 
but absent in terminal ampullae (B).  In the capillary loop stage, premature renal proximal tubules 
express RC3 (E) and cadherin-6 (F), but are E-cadherin-negative (G).  Alpha-catenin is expressed in 
induced nephrogenic blastemal cells, in terminal ampullae, and in all developing nephron segments 
throughout nephron development (D and H). 
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Fig. 2: Expression of E-cadherin, cadherin-6 and α-catenin during kidney development and in RCC.  
The expression patterns of cadherins appear to be fixed at the S shaped body stage, i.e., in a relatively 
early stage of nephron development.  It is hypothesized that low grade renal cell carcinoma cells 
probably express the same molecules as the normal cells from they are derived.  In addition, 
Undifferentiated tumor which expresses neither E-cadherin nor cadherin-6 expresses α-catenin 
heterogeneously (combined positive and negative part). 
 
   
 
 
 
Fig. 3: In normal
adult kidney, renal
proximal tubules
do not express
E-cadherin but
cadherin-6 and
α-catenin (A, B
and C,
respectively), 
delineated by
immunoreactivity 
with RC3
monoclonal 
antibody (D).  In
contrast, renal
distal tubules
express 
E-cadherin (A)
and α-catenin (C). 
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Table 1  Cadherin expression and histological subtype of RCC  
       E-cadherin(+)       E-cadherin(-) 
 Cadherin-6  + -  + - total 
alveolar type 
 clear   7 0  13 2 22 
 granular  2 1  6 2 11 
 mixed   0 2  4 1 7 
papillary   0 0  0 1 1 
tubular    1 0  1 0 2 
total    10 3  24 6 43 
  +: positive;  -: negative 
 
 
Clinico-pathological analysis in association with aberrant cadherin expression in 
RCC 
 Normal, heterogeneous, or absent expression of cadherin-6 was observed in 
19, 15, or 9 of 43 RCCs, respectively, whereas in 11, 2, or 30, in E-cadherin 
expression, respectively.  Expression pattern of cadherin-6 correlated with tumor 
stage and grade better than E-cadherin (p=0.016 and 0.012 for cadherin-6 vs 0.038 
Fig. 4: In typical
renal cell
carcinoma, 
E-cadherin is
completely absent
(A), whereas
homogenous 
cadherin-6 
expression can be
observed at the
cell-cell borders
(B).  In some
cases, e.g., clear
cell carcinoma
grade 2,
co-expression of
E-cadherin (C)
and cadherin-6 (D)
was observed. 
 
Chapter 5
 
76 
and 0.947 for E-cadherin).  In survival curves, patients who had tumors with 
abnormal expression of cadherin-6 had a poor survival compared with patients with 
normal expression of cadherin-6 (p=0.0009).  In contrast, abnormal expression of 
E-cadherin did not correlate with poor survivals in patients with RCC (p=0.265) as 
reported in our previous study [13]. 
 
 
Discussion 
In this study we show that dramatic changes occur in cadherin/catenin 
expression during nephron development.  However, beyond the S-shaped body 
stage, the first morphological structure where the fate of every component has been 
described [14], cadherin expression appears to be completely determined. I.e., 
cadherin expression seems to be fixed at an early stage of nephron development.  
At renal vesicle induction, radical changes occur in the phenotype of the induced 
metanephric blastemal cells [15].  This is also true for cadherin expression.  For 
example, cadherin-6 expression is induced and expressed in all structures known to 
give rise to proximal epithelial cells whereas no expression can be observed in 
blastemal cells.  This coincides with expression of cytokeratin 8 and 18, 
cytokeratins specific for simple epithelia[15].  Thus, metanephric blastemal cells 
abruptly change from a mesenchymal to an epithelial phenotype.   
In a recent report Cho et al. also described heterogeneous cadherin-6 expression 
by renal vesicles and suggested that this primitive epithelium is already patterned 
with respect to progenitor cell types [16].  In contrast to our observations, these 
investigators observed E-cadherin in renal vesicles as well. Otherwise, our 
immunohistochemical observations are in complete agreement: in the S-shaped 
body, the cadherin expression patterns reflect the developmental fate of each region.  
The staining results for E-cadherin in the developing nephron are also in agreement 
with Nouwen et al. who described the expression of A-CAM (N-cadherin) and 
L-CAM (E-cadherin) in human developing kidney [4].  These investigators 
described N-cadherin expression in lower and middle limbs of the S-shaped body in 
fetal kidney and in proximal tubules and thin limb of Henle's loop in adult kidney. 
In our study we found cadherin-6 expression in these same structures.  Thus, in 
developing and in adult nephrons N-cadherin and cadherin-6 appear to be 
co-expressed. 
We noticed that proximal tubular expression of cadherin-6 and α-catenin was 
predominantly basolateral rather than lateral at epithelial cell-cell contact sites.  
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Basolateral cadherin staining has also been observed by Piepenhagen et al. [17].  
Currently, no explanation for this basolateral staining of cadherin-6 is obvious.  
Piepenhagen et al. [17] hypothesized that this staining pattern might be due to 
intracellular cadherin-cadherin interactions with the basal infoldings that 
characterize many of the cell types along the nephron.  These investigators also 
suggested that cadherin-6 might interact with the adjacent non-epithelial cell 
layers. 
In subsets of RCC, a tumor originating from proximal tubular epithelial cells 
down-regulation of cadherin-6 and up-regulation of E-cadherin was observed.  In 
the majority of RCC cadherin-6 expression was preserved: cadherin-6 was 
expressed in 79.0% of RCC, whereas E-cadherin was expressed in only 30.2%. 
However, only 24/43 RCC displayed a cadherin-6+/E-cadherin- phenotype.  
Co-expression of cadherin-6 and E-cadherin was observed in 10 cases and three 
RCC expressed E-cadherin exclusively. Additionally, six RCC failed to express 
cadherin-6 as well as E-cadherin, whereas heterogeneous α-catenin was observed. 
Thus in 44% of RCC the cadherin expression pattern was dissimilar to the 
expression pattern of the cells of origin.  Apparently, the neoplastic transformation 
of proximal tubular epithelial cells leads to major alterations in expression of these 
critical molecules in almost half of the tumors.  This contrast with the expression 
of other cytoskeletal molecules in RCC e.g., cytokeratin which is almost invariably 
identical to the cells of origin [15].  This dissimilarity can be explained by the 
different function of these different classes of molecules: intermediate filaments are 
involved in maintenance of cellular structure, whereas cadherin molecules are 
involved in cell-adhesion processes, i.e., organ structure.  The altered cadherin 
expression may be a reflection of degree of dedifferentiation from primary organ.  
In three RCC exclusive expression of E-cadherin was seen.  These tumors may 
constitute tumors originating from more distal tubular elements.  The six tumors 
that failed to express cadherin-6 as well as E-cadherin, combined with 
heterogeneous α-catenin expression may consist of extremely aggressive cells with 
high metastatic capacity, as loss of α-catenin in RCC is known to correlate with poor 
clinical outcome in RCC [8].  Previous studies have also reported on E-cadherin 
expression in RCC [8,18].  Since more than 90% of RCC are thought  to arise from 
renal proximal tubular cells based on their common phenotype [13, 15, 19, 20], it is 
not surprising that only a minority of RCC express E-cadherin.  This E-cadherin 
expression can be explained by up-regulation of E-cadherin during kidney 
carcinogenesis.  
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In present and previous study, we demonstrated that normal expression of 
cadherin-6 was a better prognostic marker than E-cadherin in RCC patients [13].  
Katagiri et al. [18] suggested a statistically significant correlation between loss of 
E-cadherin expression and advanced stages of RCC.  In other tumor types where 
the progenitor cells express E-cadherin, loss of E-cadherin is considered an 
important step in the development of invasion or metastatic potential [22-24].  
However, in view of the absence of E-cadherin expression in proximal tubular cells 
absence of E-cadherin in RCC does not signify loss of E-cadherin expression, and it 
is difficult to envision how absence of E-cadherin is correlated with stage.  Gunji et 
al. [25] reported that E-cadherin positive pancreatic cancer cells more frequently 
metastasized to the liver than E-cadherin negative cells, indicating that loss of 
E-cadherin expression might promote detachment from the primary tumor, whereas 
E-cadherin expression might be helpful to attach to target organs.  However, the 
former is clearly not the case for RCC, as a positive correlation existed between 
absence of E-cadherin expression and more advanced stage [18].  Considering the 
potential of prognostic indicator, no significant difference in prognosis was observed 
between 44% of RCC with altered combination of cadherins and the other tumors 
(data not shown).  This indicated that scoring of expression pattern including 
normal and heterogeneous should be taken into account to estimate malignant 
potential of the tumor.   
The histopathological features of RCC did not correlate with the expression 
patterns of cadherin-6 and E-cadherin, similar to the findings of Paul et al. [26].  
The current WHO pathological classification system [9] is not based on a phenotypic 
comparison between the tumor cells and their presumed progenitor cell.  Thoenes 
et al. [27] described a histopathological classification system for RCC based on cell 
type, growth pattern and cytological grading of malignancy.  With this 
classification system a correlation between cadherin expression pattern and tumor 
type might be possible.  In further studies it will be of great interest to compare 
cadherin expression pattern with the Thoenes classification [27, 28].  
In summary, the nephron expresses a complex set of cadherins, and the 
cadherin expression patterns reflect the developmental fate of each region at a 
relatively early stage of nephron development.  During carcinogenesis, cadherin 
expression changes in almost 50% of RCC.  In view of the critical function of these 
molecules, particularly with respect to cell-adhesion, precise definition of cadherin 
expression patterns in RCC might eventually be helpful in defining patients at risk 
for recurrence.  
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Summary and general discussion 
 
The clinical course of renal cell carcinoma (RCC) patients is unpredictable. 
Although the extent of tumor spread at the time of diagnosis closely correlates with 
survival, patients with seemingly localized disease may still develop metastases 
even several years after surgery. Tumor nephrectomy remains the only possibility 
for cure in patients with localized disease. For patients with advanced disease the 
mean survival (approximately 8-12 months) has not significantly increased during 
the last 20 years, despite the implementation of e.g. interleukin-2 (IL-2), 
interferon-alpha (IFN) and combination therapy. New targeted therapeutics for 
RCC are becoming available (e.g. Sorafenib and Sunitinib), but their impact on 
survival is currently unclear. Clinically most patients respond by temporary 
stabilization of metastatic disease, i.e., progression-free survival is improved. 
Stratification of patients into different prognostic/responder groups would be 
highly beneficial: it would enable identification of patient more likely to respond, 
thus preventing over-treatment. Secondly, it would have implications for clinical 
counseling of patients regarding expected survival or time to disease progression. 
Existing accepted prognostic markers for RCC are tumor spread and grade. Clearly, 
it is imperative to search for new markers that can distinguish different prognostic 
groups.  
Chapter 1 reviews molecular prognostic factors in RCC and the necessity to 
determine prognostic tumor markers, with emphasis on metastatic potential, to 
identify the patients who are at risk for metastasis after nephrectomy.  Particular 
attention is paid to the cell adhesion molecule E-cadherin, a Ca++-dependent 
cell-cell adhesion molecule. This molecule plays an essential role in preserving 
tissue integrity in many epithelia. In various carcinomas aberrant E-cadherin 
expression has been correlated with metastatic potential and can serve as 
prognostic marker. A large cell adhesion complex is formed through protein-protein 
interactions of the intracellular domain of E-cadherin with other proteins (a.o. α-, 
β-, γ-catenin) linking it to the actin filaments. However, in RCC, the expression of 
E-cadherin is very low, probably because E-cadherin is not expressed in normal 
renal proximal tubular epithelium, from which RCC originates. In addition, the 
function of cadherin is usually modulated by catenins.  In this study, we focused 
on identifying which cadherin is expressed in RCC and its role in the metastatic 
potential of the tumor, and we also investigated expression of the cadherin-catenin 
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complex in RCC and normal kidney. 
In Chapter 2, cadherin expression of RCC is described, as determined by 
immunoprecipitation techniques. In these pull-down assays seven RCC cell lines 
were investigated using an anti-α-catenin antibody as catcher antibody. Clear 
expression of β-catenin, γ-catenin, and cadherins other than E-cadherin was 
observed. By RT-PCR several cadherins were detected in these cell lines (N-, -6, -11, 
-4, E- and P- cadherin). Northern blot analyses and Western blot analyses 
demonstrated the frequent expression of N- and cadherin-6 in 20 RCC cell lines, 
whereas expression of cadherin-11 and -4 was rare. Therefore, we concluded that 
cadherin-6 and N-cadherin are the major cadherins in RCC cell lines and are the 
most likely candidates to participate in a cell adhesion complex. 
Because cadherin expression has been correlated with prognosis in other 
carcinomas, we investigated the value of cadherin-catenin expression as a 
prognostic marker. In Chapter 3, expression of E-cadherin, three catenins, and 
p120cas in frozen tissue of 90 RCC specimens as determined by 
immunohistochemistry, and their significance as prognostic markers was 
evaluated. The staining pattern was scored as normal (homogeneously positive at 
cell-cell borders) or abnormal (heterogeneous or absent). A significant correlation 
between poor survival and decreased expression of α-, β-, and γ-catenin was 
observed, whereas no association between survival and E-cadherin or p120cas 
expression was seen.  Cox's proportional hazard regression analysis showed that 
reduced α-catenin expression correlated with poor survival rates in patients with 
pT1-3N0M0 disease, suggesting that α-catenin expression might be an 
independent prognostic indicator for this group of patients.  In addition, the fact 
that loss of function of either E-cadherin or cadherin-6 results in abnormal 
α-catenin expression is explaining the strongest prognostic value of α-catenin in 
RCC.  
In view of the strong cadherin-6 expression observed in RCC cell lines, we 
hypothesized that cadherin-6 might be important in cell-cell adhesion in the kidney. 
Chapter 4 describes an immunohistochemical study where the relationship 
between prognosis and cadherin-6 expression of the tumors of 43 patients with 
RCC was examined. After developing a cadherin-6 specific monoclonal antibody 
the immunohistochemical study showed normal, heterogeneous, and absence of 
cadherin-6 in 19, 16, and 8 of 43 cases, respectively. Co-expression of E-cadherin 
and cadherin-6 was detected in only 10 cases. Of 30 tumors without E-cadherin 
expression, 24 tumors expressed cadherin-6, emphasizing the importance of 
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cadherin-6 for renal tissue. In addition, the expression pattern of α-catenin 
correlated better with that of cadherin-6 than with E-cadherin (p=0.0003 vs. 0.025). 
This suggests that loss of α-catenin, a molecule that is an integral part of all 
cadherin complexes, is more important in predicting prognosis than cadherin 
expression pattern. In survival analyses, aberrant expression of cadherin-6 
correlated with poor survival both in all patients (p=0.0009) and in patients with 
E-cadherin-negative RCC (p=0.0008).  These results suggested that cadherin-6 is 
the major cadherin in renal tissue, playing an essential role in cell-cell adhesion in 
E-cadherin-negative RCC.  
Finally we studied alterations of the cadherin-catenin complex during normal 
kidney development and during neoplastic change because during tissue 
remodeling processes, such as organ development and tumorigenesis, cell-cell 
adhesion may be modified to allow morphogenic movement. In Chapter 5, the 
pattern of cadherin expression in fetal, adult, and neoplastic kidney is described. A 
complex expression pattern of a combination of cadherins was observed in a 
relatively early phase of nephron development. Cadherin-6 was expressed in the 
lower and middle limbs of the S-shaped bodies, structures that will develop into 
renal proximal tubules, which also express cadherin-6. Similarly, E-cadherin was 
expressed in the upper limb of the S-shaped body that will develop into distal and 
collecting tubules, also expressing E-cadherin. Thus, already at a very early phase 
of nephron development cadherin expression patterns are identical to the mature 
nephron. On the other hand, the immunohistochemical analysis clearly showed 
cadherin-6 and E-cadherin in RCC expression. This demonstrates that cadherin 
expression in RCC can be aberrant, and dissimilar from normal kidney. Although 
one could argue that a subcategory of RCC may rise from a different part of in the 
nephron [1-4], there is ample evidence that the majority of RCC arise from 
proximal tubular cells based on e.g. phenotypic analyses. Evance et al. [5] reported 
that mutation of the von Hippel Lindau (VHL) gene, which is detected in 60% of 
clear cell RCC, may cause down-regulation of E-cadherin expression and may 
results in acquisition of a more invasive phenotype, it is possible that in 
E-cadherin-positive RCC VHL is still functional and this might drive E-cadherin 
expression under aberrant conditions. 
In the recent literature, expression of cell adhesion molecules and cadherins in 
RCC was further investigated by Paul, et al. [6] and they also reported that 
cadherin-6 was expressed in RCC rather than E-cadherin is concordance with our 
studies. The prognostic value of cadherin-6 seemed to be significance but should be 
Summary and discussion 
 
 87 
investigated in future studies. We have also studied the function of several 
cadherins expressed in RCC cell lines, by means of inhibition of cell attachment 
during cellular spheroid formation on spheroid culture plate using specific 
antibodies against the extra cellular domain of cadherins [7]. In this study, we 
found that E-cadherin and cadherin-6 played a dominant role on cell-cell adhesion, 
whereas N-cadherin functioned as a cell adhesion molecule when function of both 
E-cadherin and cadherin-6 was impaired. We also reported that expression of 
N-cadherin is associated with poor prognosis of patients with RCC, suggesting that 
N-cadherin does not properly function as a cell adhesion molecule in RCC [8].  
These facts suggest that N-cadherin might play a role in epithelial stromal 
interaction in invasive RCCs, in which E-cadherin and cadherin-6 are frequently 
impaired. De novo expression of N-cadherin can be associated with epithelial to 
mesenchymal transition and this has been correlated with poor survival of patients 
in other malignancies, e.g. breast cancer and prostate cancer [9, 10].  
Using quantitative RT-PCR for cadherin-6 we tested whether circulating RCC 
cells could be detected in peripheral blood. Detection of high cadherin-6 mRNA 
levels in the blood at the time of diagnosis correlated with future metastasis of 
RCC after nephrectomy [11, 12]. This coincides with the fact that the expression 
pattern of cadherin-6 was normal or heterogeneous rather than absent in most 
RCCs in our previous study. 
In terms of other molecular prognostic factors in RCC, expression of carbonic 
anhydrase IX (CAIX), hypoxia-inducible factor 1α (HIF1α), and several cell cycle 
regulators have been studied. The hypoxia-inducible pathway plays an essential 
role in angiogenesis, pH, epithelial proliferation, and apoptosis of common cancers 
including RCC.  HIF1α protein is controlled at the posttranscriptional level by 
hypoxia through the von Hippel-Lindau (VHL) tumor suppressor protein [13]. 
Under normoxic conditions, HIF1α binds to VHL and this is rapidly degraded by 
the ubiquitin-proteosome pathway, whereas under hypoxic conditions HIF1α does 
not bind to VHL, and is thus is not subject to degradation [14]. Accordingly, 
mutation, deletion, or hypermethylation of the VHL gene causes the intracellular 
accumulation of HIF1α even in the absence of hypoxia. The VHL-HIF tumorgenic 
pathway is well known for clear cell RCC. Lidgren, et al. [15] reported on the role 
of HIF-1α in determining the prognosis in a cohort of 92 patients undergoing 
nephrectomy. Increased HIF-1α expression was an independent predictor of 
survival for clear cell RCC [16].   
CA IX, a member of the carbonic anhydrase family, regulates intracellular and 
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extra cellular pH during periods of hypoxia.  CA IX expression is mediated by the 
HIF transcriptional complex that is induced in many tumor types, but is absent in 
most normal tissues. Bui et al. [17] reported that 94% of clear cell RCC samples 
expressed CA IX and that overall expression of CA IX decreased with development 
of metastasis. Low CA IX staining (85% or less) was found to be an independent 
poor prognostic marker for the patients with metastatic RCC. In addition, higher 
CA IX expression (more than 85%) was associated with a good response to 
interleukin-2 (IL-2) immunotherapy, suggesting that CA IX expression may predict 
response to IL-2 therapy [18]. The highly specific expression of CA IX by RCC 
makes it an attractive candidate for vaccine development. Indeed, CA 
IX-transduced T lymphocytes were capable of lysing CA IX expressing cancer cells 
in vitro [19, 20]. Thus, CA IX is not only useful as a prognostic marker but also a 
potential therapeutic target in RCC. 
Most recently, cDNA or tissue array-based analyses provided a cluster of 
potential genetic or molecular prognostic markers for RCC.  Several studies 
suggested a new classification system, based on a nomogram [21-25]. Togashi et al. 
[26] reported that hypoxia-inducible gene-2 (HIG-2) protein, which was detected by 
cDNA microarray expression analysis, might be associated with tumorigenesis and 
tumor development of clear cell RCC. HIG-2 levels appeared to predict the 
presence of residual tumor after treatment. An optimal combination of these 
molecular markers may allow a personalized, individualized treatment for the 
patient with RCC. 
In conclusion, the collective evidence from our studies suggests that the 
determination of the molecular signature in RCC, including cadherin/catenin 
expression, can be used as a new diagnostic tool to stratify patients for prognosis 
and recurrence of disease. Although larger studies are necessary to confirm these 
results, cadherin expression might be a valuable new prognostic molecular marker. 
From a therapeutic point of view, cadherin-6 might be an interesting new 
candidate for future targeted therapy in RCC. 
 
 
References 
1. Adley BP, Gupta A, Lin F, Luan C, Teh BT, Yang XJ. Expression of kidney-specific 
cadherin in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin 
Pathol. 2006;126:79-85.  
 
Summary and discussion 
 
 89 
2. Thedieck C, Kuczyk M, Klingel K, Steiert I, Muller CA, Klein G. Expression of 
Ksp-cadherin during kidney development and in renal cell carcinoma. Br J Cancer. 
2005;92:2010-2017.  
 
3. Shen SS, Krishna B, Chirala R, Amato RJ, Truong LD. Kidney-specific cadherin, 
a specific marker for the distal portion of the nephron and related renal neoplasms. 
Mod Pathol. 2005;18:933-940.  
 
4. Blaschke S, Mueller CA, Markovic-Lipkovski J, Puch S, Miosge N, Becker V, 
Mueller GA, Klein G. Expression of cadherin-8 in renal cell carcinoma and fetal 
kidney. Int J Cancer. 2002;101:327-334.  
 
5. Evans AJ, Russell RC, Roche O, Burry TN, Fish JE, Chow VW, Kim WY, 
Saravanan A, Maynard MA, Gervais ML, Sufan RI, Roberts AM, Wilson LA, 
Betten M, Vandewalle C, Berx G, Marsden PA, Irwin MS, Teh BT, Jewett MA, Ohh 
M. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated 
regulation of SIP1 and snail. Mol Cell Biol. 2007;27:157-169. 
 
6. Paul R, Necknig U, Busch R, Ewing CM, Hartung R, Isaacs WB. Cadherin-6: a 
new prognostic marker for renal cell carcinoma. J Urol 2004;171:97-101.  
 
7. Shimazui T, Schalken JA, Kawai K, Kawamoto R, van Bockhoven A, Oosterwijk 
E, Akaza H. Role of complex cadherins in cell-cell adhesion evaluated by spheroid 
formation in renal cell carcinoma cell lines. Oncol Rep 2004;11:357-360.  
 
8. Shimazui T, Kojima T, Onozawa M, Suzuki M, Asano T, Akaza H.  Expression 
profile of N-cadherin differs from other classical cadherins as a prognostic marker 
in renal cell carcinoma. Oncol Rep. 2006 May;15(5):1181-4.  
 
9. Hazan RB, Kang L, Whooley BP, Borgen PI. N-cadherin promotes adhesion 
between invasive breast cancer cells and the stroma. Cell Adhes Commun. 
1997;4:399-341 
 
10. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, 
Bussemakers MJ, Schalken JA. Cadherin switching in human prostate cancer 
progression. Cancer Res. 2000;60:3650-3654.  
Chapter 6
 
 
90 
11. Shimazui T, Yoshikawa K, Uemura H, Hirao Y, Saga S, Akaza H. The level of 
cadherin-6 mRNA in peripheral blood is associated with the site of metastasis and 
with the subsequent occurrence of metastases in renal cell carcinoma. Cancer 
2004;101:963-968.  
 
12. Li G, Passebosc-Faure K, Gentil-Perret A, Lambert C, Genin C, Tostain J. 
Cadherin-6 gene expression in conventional renal cell carcinoma: a useful marker 
to detect circulating tumor cells. Anticancer Res 2005;25:377-381.  
 
13. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, 
Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein 
VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 
1999;399:271-275. 
 
14. Shuch BM, Lam JS, Belldegrun AS, Figlin RA. Prognostic factors in renal cell 
carcinoma. Semin Oncol 2006;33:563-575. 
 
15. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B. The 
expression of hypoxia-inducible factor 1alpha is a favorable independent 
prognostic factor in renal cell carcinoma. Clin Cancer Res 2005;11:1129-1135. 
 
16. Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, 
Stanbridge EJ, Palotie A, Figlin RA, Belldegrun AS. Prognostic value of carbonic 
anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J 
Urol 2004;171:2461-2466.  
 
17. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, 
deKernion JB, Figlin RA, Belldegrun AS.Improved prognostication of renal cell 
carcinoma using an integrated staging system. J Clin Oncol 2001;19:1649-1657. 
 
18. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, 
Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, 
Belldegrun AS. Carbonic anhydrase IX is an independent predictor of survival in 
advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin 
Cancer Res 2003;9:802-811. 
 
Summary and discussion 
 
 91 
19. Vissers JL, De Vries IJ, Schreurs MW, Engelen LP, Oosterwijk E, Figdor CG, 
Adema GJ. The renal cell carcinoma-associated antigen G250 encodes a human 
leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T 
lymphocytes. Cancer Res 1999;59:5554-5559. 
 
20. Vissers JL, De Vries IJ, Engelen LP, Scharenborg NM, Molkenboer J, Figdor 
CG, Oosterwijk E, Adema GJ. Renal cell carcinoma-associated antigen G250 
encodes a naturally processed epitope presented by human leukocyte antigen-DR 
molecules to CD4(+) T lymphocytes. Int J Cancer 2002;100:441-444. 
 
21. Lam JS, Belldegrun AS, Firglin RA. Tissue array-based predictions of 
pathology, prognosis, and response to treatment for renal cell carcinoma. Clin 
Cancer Res 2004;10:6304s-6309s. 
 
22. Lam JS, Leppert JT, Figlin RA, Belldegrun As. Role of molecular markers in 
the diagnosis and therapy of renal cell carcinoma. Urology 2005;66:1-9. 
 
23. Shi T, Seligson D, Belldegrun AS, Palotie A, Horvath S. Tumor classification by 
tissue microarray profiling: random forest clustering applied to renal cell 
carcinoma. Mod Pathol 2005;18:547-557. 
 
24. Fukata S, Inoue K, Kamada M, Kawada C, Furihata M, Ohtsuki Y, Shuin T.  
Levels of angiogenesis and expression of angiogenesis-related genes are prognostic 
for organ-specific metastasis of renal cell carcinoma. Cancer. 2005;103:931-942.  
 
25. Li G, Cuilleron M, Gentil-Perret A, Cottier M, Passebosc-Faure K, Lambert C, 
Genin C, Tostain J. differential diagnosis of renal cell carcinoma. Clin Cancer Res. 
2003;9:6441-6446.  
 
26. Togashi A, Katagiri T, Ashida S, Fujioka T, Maruyama O, Wakumoto Y, 
Sakamoto Y, Fujime M, Kawachi Y, Shuin T, Nakamura Y. Hypoxia-inducible 
protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential 
target for molecular therapy. Cancer Res 2005;65:4817-4826. 
 
 
 
Chapter 6
 
 
92 
 
 
 
Samenvatting en discussie 
 
93 
Samenvatting en discussie 
Het klinisch beloop van nierkanker (NC) patiënten is onvoorspelbaar. Hoewel 
de mate van tumor uitbreiding op het moment van diagnose goed correleert met de 
overleving kunnen patiënten met gelokaliseerde ziekte toch uitzaaiingen 
ontwikkelen, zelfs jaren na operatie. Resectie van de tumor blijft de enige 
mogelijkheid op genezing voor patiënten met gelokaliseerde ziekte. De gemiddelde 
overlevingsverwachting voor patiënten met gemetastaseerde ziekte is ongeveer 
8-12 maanden. Deze is de afgelopen 20 jaar niet significant veranderd, ondanks 
inzet van bijvoorbeeld interleukine-2 (IL-2), interferon-alpha (IFN) en combinatie 
therapie. Nieuwe, doelgerichte therapeutische middelen zoals Sorafenib en 
Sunitinib komen voor de behandeling van NC patiënten beschikbaar, maar het 
effect op overleving is momenteel onduidelijk. De meeste patiënten reageren met 
een tijdelijke stabilisatie van het ziekte proces, d.w.z. dat de progressie-vrije 
periode verlengt wordt. Onderverdeling van patiënten in groepen met 
verschillende prognose/ reactie op therapie zou wenselijk zijn: zo zouden patiënten 
geïdentificeerd kunnen worden waarvan het het meest waarschijnlijk is dat ze 
responderen, zodat overbehandeling vermeden kan worden. Daarnaast zal 
onderverdeling in risico-groepen consequenties hebben voor voorlichting van 
patiënten v.w.b. hun verwachtte overleving of tijd tot progressie. Huidige 
geaccepteerde prognostische factoren voor NC zijn tumor uitbreiding en graad. Het 
is duidelijk dat gezocht moet worden naar nieuwe markers die patiënten met een 
verschillende prognose kunnen onderscheiden.  
In hoofdstuk 1 worden moleculaire prognostische factoren in NC en de 
noodzaak voor het bepalen van prognostische factoren behandeld. De nadruk ligt 
daarbij op het voorspellen van het metastaserende vermogen van de tumor om zo 
patiënten te kunnen identificeren die een hoog risico lopen op het ontwikkelen van 
uitzaaiingen na nefrectomie. Er wordt vooral aandacht besteed aan het celadhesie 
molecuul E-cadherine, een Ca++-afhankelijk cel-cel adhesie molecuul. Dit molecuul 
speelt een essentiële rol in het handhaven van de weefsel integriteit van vele 
epithelia. Voor verschillende carcinomen is aangetoond dat afwijkende E-cadherine 
expressie correleert met verhoogd metastaserend gedrag en dit zou kunnen dienen 
als prognostische factor. Door eiwit-eiwit interacties van het intracellulaire domein 
van E-cadherine met andere eiwitten, zoals α-, β-, γ-catenine catenine, wordt een 
groot celadhesie complex gevormd dat aan actine filamenten bind. De expressie 
van E-cadherine in NC is erg laag, waarschijnlijk omdat E-cadherine niet tot 
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expressie komt in normale proximale tubuli in de nier, cellen waaruit NC ontstaat. 
Daarnaast wordt de functie van cadherines meestal gemoduleerd door catenines. 
In deze studie is hebben we ons gericht op het identificeren van het cadherine dat 
door NC tot expressie gebracht wordt, en op de rol die dit cadherine speelt bij de 
agressiviteit van de tumor. Daarnaast is ook de expressie van het 
cadherine-catenine complex in NC en normaal nierweefsel onderzocht.  
In Hoofdstuk 2 is de cadherine expressie in NC beschreven, bepaald met 
behulp van immuunhistochemische technieken. Zeven NC cellijnen werden 
onderzocht waarbij een zelf geproduceerd anti α-catenine antilichaam gebruikt is. 
Duidelijke expressie van β-catenine, γ-catenine, en cadherines anders dan 
E-cadherine werd gezien. Door middel van RT-PCR werden verschillende 
cadherines gedetecteerd in deze cellijnen (N-, -6, -11, -4, E- and P- cadherine). 
Northern blot analyse and Western blot analyse lieten een frequente expressie van 
N- en cadherine-6 zien in 20 NC cellijnen, terwijl expressie van cadherine-11 en -4 
zelden waargenomen werd. Op basis van deze resultaten is geconcludeerd dat 
cadherine-6 en N-cadherine de meest voorkomende, belangrijkste cadherines zijn 
in NC cellijnen en dat dit de meest waarschijnlijke kandidaten zijn om te 
participeren in een cel-cel adhesie complex in NC.  
Omdat voor andere tumoren bekend is dat cadherine expressie correleert met 
prognose, is bestudeerd wat de waarde is van cadherine-catenine expressie als 
prognostische marker voor NC. In Hoofdstuk 3 worden immuunhistochemische 
studies beschreven waarbij de expressie van E-cadherine, drie catenines, en 
p120cas bestudeerd is in vriesmateriaal van 90 NC specimens en is hun relevantie 
als eventuele prognostische factor geëvalueerd. Het kleurpatroon werd beoordeeld 
als normaal (homogeen positief aan cel-cel contacten) of afwijkend (heterogeen of 
afwezig). Er werd een significante correlatie gevonden tussen slechte overleving en 
afname van expressie van α-, β-, en γ-catenine, terwijl er geen associatie gevonden 
werd tussen overleving en E-cadherine of p120cas expressie. Cox's proportional 
hazard regressie analyse toonde aan dat verminderde α-catenine expressie 
correleerde met slechte overleving voor pT1-3N0M0 patiënten. Dit suggereert dat 
α-catenine expressie kan dienen als een onafhankelijke prognostische factor voor 
deze groep patiënten. Het feit dat verlies van functioneel E-cadherine of 
cadherine-6 leidt tot afwijkende α-catenine expressie verklaard waarom 
α-catenine de sterkste prognostische waarde heeft in NC.  
Gezien de sterke cadherine-6 expressie in NC cellijnen lijkt het waarschijnlijk 
dat cadherine-6 belangrijk is bij cel-cel adhesie in nierweefsel. Hoofdstuk 4 
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beschrijft een immuunhistochemische studie waarbij de relatie tussen prognose en 
cadherine-6 expressie onderzocht is in tumoren van 43 patiënten met NC. 
Allereerst is een cadherine-6 specifiek monoklonaal antilichaam geïsoleerd. In de 
immuunhistochemische studie werd een normaal, heterogeen en geen expressie 
gezien van cadherine-6 in respectievelijk 19, 16, en 8 van de 43 gevallen. 
Co-expressie van E-cadherine en cadherine-6 werd gedetecteerd in slechts 10 
gevallen. Van de 30 tumoren zonder E-cadherine expressie vertoonden 24 expressie 
van cadherine-6, dit benadrukt het belang van cadherine-6 voor nierweefsel. 
Daarnaast correleerde het expressie patroon van α-catenine beter met dat van 
cadherine-6 dan met E-cadherine (p=0.0003 vs 0.025). Dit suggereert dat verlies 
van α-catenine, een molecuul dat een integraal onderdeel is van alle cadherine 
complexen belangrijker is voor het voorspellen van de prognose dan het cadherine 
expressie patroon. In de analyse van de overleving van de patiënten bleek 
afwijkende expressie van cadherine-6 te correleren met slechte overleving, zowel 
voor alle patiënten samen (p=0.0009) als voor patiënten met 
E-cadherine-negatieve NC (p=0.0008).  Deze resultaten suggereren dat 
cadherine-6 inderdaad het belangrijkste cadherine is voor nierweefsel, waar het 
een essentiële rol speelt bij de cel-cel adhesie in E-cadherine-negatieve NC.  
Als laatste zijn veranderingen van het cadherine-catenine complex gedurende 
de ontwikkeling van de nier en gedurende neoplastische veranderingen bestudeerd 
omdat gedurende weefsel remodelling, zoals de ontwikkeling van een orgaan en 
tumorgenese, cel-cel adhesie gemodificeerd kan worden om morphogenetische 
beweging toe te staan. Hoofdstuk 5 beschrijft het cadherine expressie patroon in 
foetaal, adult, en neoplastisch nierweefsel. Er werd een complex expressie patroon 
waargenomen in een relatieve vroege fase van nephron ontwikkeling. Cadherine-6 
werd tot expressie gebracht in de lage en middelste delen van de S-vormige 
lichamen, structuren die zich uiteindelijk ontwikkelen tot proximale tubuli die ook 
cadherine-6 tot expressie brengen. E-cadherine werd tot expressie gebracht in de 
bovenste delen van het S-vormige lichaam dat zich zal ontwikkelen in distale 
tubuli en verzamelbuizen, die ook E-cadherine tot expressie brengen. Kortom, al in 
een zeer vroeg stadium van nephron ontwikkeling zijn de cadherine expressie 
patronen identiek aan mature nephron. Echter, de immuunhistochemische analyse 
van NC toonde duidelijk zowel cadherine-6 als E-cadherine aan in NC. Dit maakt 
duidelijk dat de cadherine expressie in NC af kan wijken van normaal nierweefsel. 
Hoewel men kan beargumenteren dat een subcategorie van NC afkomstig kan zijn 
van andere delen van het nephron, [1-4], is er overweldigend bewijs dat de 
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overgrote meerderheid van NC afkomstig is uit cellen van het tubulaire epitheel, 
bijvoorbeeld d.m.v. fenotypische analyses. In de studie van Evance et al. [5] werd 
gerapporteerd dat VHL mutatie, die in ongeveer 60% van heldercellig NC 
gevonden wordt, vermindering van E-cadherine kan bewerkstelligen en dit zou 
kunnen leiden tot een meer agressief fenotype. Het is mogelijk dat in 
E-cadherine-positieve NC functioneel VHL aanwezig is hetgeen E-cadherine 
expressie onder afwijkende condities kan bewerkstelligen.  
In de studie van Paul et al. [6], waar ook expressie van cel adhesie moleculen 
en cadherines in NC onderzocht is, vermelden de onderzoekers ook dat cadherine-6 
tot expressie gebracht wordt in NC, en niet E-cadherine, in overeenstemming met 
onze waarnemingen. Tevens bleek de waarde van cadherine-6 als prognostische 
factor significant. Verdere studies zijn nodig om tot een uitspraak te komen. De 
functie van verschillende cadherines in NC cellijnen is ook onderzocht d.m.v. 
inhibitie van cel binding gedurende sfeer-formatie waarbij gebruik gemaakt werd 
van specifieke antilichamen gericht tegen het extracellulaire domein van 
cadherines [7]. Daarin werd gevonden dat cadherine-6 en E-cadherine 
voornamelijk een rol spelen bij cel-cel adhesie, terwijl N-cadherin slechts als 
celadhesie molecuul fungeerde als de functie van zowel cadherine-6 en E-cadherine 
verstoord was. Expressie van N-cadherine is geassocieerd met een slechte prognose 
van NC patiënten, suggererend dat N-cadherine niet correct functioneert als 
cel-cel adhesie molecuul in NC [8]. Wellicht speelt N-cadherine een rol bij de 
epitheel-stroma interacties in invasief NC, waar E-cadherine en cadherine-6 vaak 
niet goed functioneren. De novo expressie van N-cadherine is geassocieerd met 
epitheel-mesenchymale transitie en slechte overleving van patiënten in andere 
maligniteiten, zoals borst en prostaat kanker [9, 10].  
In andere studies is met kwantitatieve RT-PCR onderzocht of cadherine-6 
mRNA circulerende NC cellen kan detecteren. Inderdaad bleek dat hoge 
cadherine-6 mRNA niveaus in het bloed op het moment van diagnose correleert 
met metastasering na nefrectomie [11, 12]. Dit komt overeen met de observatie van 
onze eerdere studie waarin bleek dat het expressie patroon van cadherine-6 in de 
meeste NC normaal of heterogeen was en niet afwezig. 
Verschillende andere moleculaire factoren in NC, zoals expressie van carbonic 
anhydrase IX (CAIX), hypoxie-induceerbare factor 1α (HIF1α), en verschillende 
regulatoren van de cel cyclus zijn door anderen bestudeerd. Het moleculaire 
mechanisme van de hypoxie-induceerbare route speelt een essentiële rol bij 
angiogenese, pH, epitheliale proliferatie en apoptose van veel carcinomen, inclusief 
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NC. HIF1α eiwit wordt op post-translationeel niveau gecontroleerd door het von 
Hippel-Lindau (VHL) tumor suppressor eiwit [13]. Bij normoxische condities bind 
HIF1α aan VHL hetgeen leidt tot snelle afbraak via de ubiquitin-proteasoom route. 
Onder hypoxische condities vind deze binding niet plaats en dan wordt HIF1α niet 
afgebroken [14]. Evenzeer leidt mutatie, deletie, of hypermethylatie van het VHL 
gen tot intracellulaire accumulatie van HIF1α, zelfs in de afwezigheid van hypoxie. 
De VHL-HIF route speelt een prominente rol in het heldercellige NC. Lidgren, et al. 
[15] rapporteerden over de rol van HIF-1α in het bepalen van de prognose in een 
cohort van 92 patiënten die een nephrectomie ondergingen. Verhoogde HIF-1α 
expressie was een onafhankelijke voorspeller van de overleving van patiënten met 
heldercellig NC [16].   
CA IX is lid van de carbonic anhydrase familie en reguleert intracellulaire en 
extra-cellulaire pH gedurende perioden van hypoxie. CA IX expressie is 
afhankelijk van het HIF transcriptie complex. Bui et al. [17] rapporteerden dat 
94% van de onderzochte heldercellige NC CA IX tot expressie brachten en dat CA 
IX expressie verminderde bij de ontwikkeling van metastasen.  Verminderde CA 
IX kleuring (85% of minder) bleek een onafhankelijke prognostische marker te zijn 
voor patiënten met gemetastaseerd NC. Daarnaast blijkt hoge CAIX expressie 
(hoger dan 85%) geassocieerd te zijn met een goede reactie op interleukine-2 (IL-2) 
immunotherapie, suggererend dat CA IX expressie de response op IL-2 therapie 
kan voorspellen [18]. De hoge, specifieke expressie van CAIX door NC maakt het 
een attractieve kandidaat voor vaccin ontwikkeling. Inderdaad blijken CA 
IX-getransduceerde periphere T cellen in staat tumor cellen die CA IX tot expressie 
brengen in vitro te lyseren [19, 20]. Daarom is CA IX niet alleen bruikbaar als 
prognostische marker maar ook een potentieel therapeutisch doel in NC. 
Een cluster van potentiële genetische en moleculaire markers voor NC is met 
behulp van cDNA en weefsel analyse geïdentificeerd. Verschillende studies hebben 
een nieuw classificatie system voorgesteld, gebaseerd op nomogrammen bestaand 
uit een aantal markers [21-25]. Togashi et al. [26] beschreven dat 
hypoxie-induceerbaar gen-2 (HIG-2) eiwit, gevonden bij een cDNA microarray 
expressie analyse, wellicht geassocieerd is met tumorgenesese en tumor 
ontwikkeling van heldercellig NC. HIG-2 niveaus lijken te wijzen op de 
aanwezigheid van tumor na behandeling. Een optimale combinatie van deze 
moleculaire markers zou een persoonlijk en individueel behandelingsschema voor 
patiënten met NC mogelijk kunnen maken. 
Concluderend suggereren onze studies dat het bepalen van een moleculaire 
Chapter 6
 
98 
handtekening, inclusief cadherine/catenine expressie, in NC gebruikt kan worden 
als een nieuw diagnostisch middel om patiënten in verschillende prognostische/ 
therapeutische klassen in te delen. Hoewel grotere studies noodzakelijk zijn om 
deze resultaten te bevestigen lijkt cadherine expressie een waardevolle nieuwe 
prognostische marker. Wellicht is cadherine-6 een interessante nieuwe kandidaat 
voor doelgerichte therapie voor NC. 
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